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ABSTRACT
Epithelial ovarian cancer (EOC) is the most common gynecologic malignancy
worldwide. EOC has a notably poor prognosis, owing to the fact that patients are
frequently diagnosed at a late stage after the disease has significantly progressed.
While many patients typically respond well to frontline platinum-based chemotherapy,
the tumor becomes chemoresistant when a recurrence follows within five years.
Therefore, there is an urgent need for the discovery of non-invasive early detection
biomarkers and novel targeted therapies.
Human Epididymis Protein 4 (HE4) is a secretory protein that is encoded by the gene
whey acidic protein (WAP)-four disulfide core domain protein 2. The WAP domain
family is a conserved motif that is inherit of many antiproteases. HE4 was initially
found to be a component of the innate immune defenses of multiple epithelia and to
function in epithelial host defense, through the promotion of mucosal surfaces first
line of defense. HE4 is highly overexpressed in EOC and has been identified as a
novel clinical biomarker. Clinical and translational studies have established HE4 as a
contributor to tumorigenesis and chemoresistance in EOC. However, the exact
processes in which HE4 promotes pathogenesis is unclear. The driving hypothesis of
this thesis is that HE4 represents a novel targeted therapy due to its established role
EOC tumorigenesis and suggested function in innate immunity. This evidence
underlies the goals of this dissertation which are to elucidate the precise mechanisms
of HE4’s contribution in EOC pathogenesis and establish HE4’s role in tumor immune
invasion. It is hoped that results from this investigation will ultimately aide in the

development of a novel targeted therapy against HE4 that can modulate tumor
pathogenesis as well as the tumor immune response.
In manuscript I, subtractive hybridization revealed that HE4 significantly suppresses
expression of osteopontin (OPN) in peripheral blood mononuclear cells (PBMCs)
which ultimately compromised their cytotoxicity against ovarian cancer cells. Ovarian
cancer cells exhibited enhanced proliferation in conditioned media from HE4-exposed
PBMCs and this effect was attenuated by the addition of recombinant OPN and OPN inducible cytokines (IL-12 and IFN-y). In addition, ovarian cancer cells and PBMCs
with HE4 downregulation via short hairpin RNA (shRNA) were found to be
increasingly more susceptible to cell death.
In manuscript II, subtractive hybridization identified dual specificity phosphatase 6
(DUSP6) as the most upregulated gene upon treatment with recombinant HE4 in
PBMCs. Flow cytometry revealed that recombinant HE4 significantly upregulated
DUSP6 levels specifically in CD8+ (cytotoxic T cell) and CD56+ (NK cell)
populations. Exposure of these cells to HE4 led to an increase in ERK ½
phosphorylation, which was subsequently decreased upon DUSP6 inhibition. These
results show that DUSP6 suppression of CD8+ and CD56+ lymphocyte toxicity is
strongly enhanced by HE4. In co-culture of PBMCs and ovarian cancer cells, DUSP6
inhibition attenuated the enhanced proliferation noted upon stimulation with HE4. The
effect of DUSP6 inhibition was obliterated in CD8+ and CD56+ devoid PBMCs.
In manuscript III, the role of DUSP6 and its relationship to HE4 in EOC was further
elucidated. Increased DUSP6 levels were observed in ovarian cancer cells
overexpressing HE4. siRNA-mediated downregulation of both HE4 and DUSP6

revealed a corresponding decrease of either factor. Treatment with an allosteric
DUSP6 inhibitor in combination with chemotherapeutic agents produced synergistic
effects on the reduction of cell viability. These effects correlated with alterations in
expression of ERK pathway mediated genes. Finally, it was found that DUSP6 was
significantly overexpressed in serous EOC patient tissue compared to normal adjacent
tissue.
In manuscript IV it was determined from a small-scale proteomics study that 63
proteins were found to interact more strongly with HE4, in HE4 overexpressing clones
compared to null vector control. The protein found to exhibit the highest interaction in
the HE4 clones was Septin-2, a GTP binding protein. Immunohistochemical analysis
of Septin-2 in EOC patient tissue revealed that levels were overexpressed in cancer
compared to normal and benign controls. To identify Septin-2’s role in EOC, stable
knockdown cell lines were constructed using the ovarian cancer cell line SKOV3.
Septin-2 knockdown cells demonstrated a significantly lowered proliferation rate
compared wild-type (WT) and Plasmid C control cells. To better define the role of
Septin-2 in EOC, proteomics was employed. Pathway analysis showed an enrichment
in
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acetyl

proteasomal/ubiquitin processes in Septin-2 knockout cells.
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PREFACE
This dissertation adopts manuscript format. It is comprised of an introduction, 4
manuscripts, and a conclusion. The format of each individual manuscript is in
accordance with the journal that they were or will be submitted to.
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CHAPTER 1

INTRODUCTION

1.1 Ovarian Cancer Incidence and Overall Survival
Worldwide ovarian cancer has an incidence of 240,000 cases per year and an annual
mortality rate of 152,000 [1]. This high mortality rate is largely due to that fact that in
many cases ovarian cancer is detected at an advanced disease state. In addition, while
the initial response rate to frontline chemotherapy is 60-80%, when the tumor recurs it
eventually becomes unresponsive to traditional platinum-based chemotherapeutics[2].
Unfortunately, only a minority of patients with advanced stage disease achieve long
term survival, as many patients will develop a recurrence within 12-18 months of
completion of their primary treatment regimen [3]. Currently, the five year survival
rate for ovarian cancer is only 35%[4] , and these dire statistics have not improved
significantly in the last 30 years[5].

1.2 Ovarian Cancer Subtypes
Ovarian Cancer is divided into two major subtypes that depend on the tissue of origin.
Non-epithelial ovarian cancer includes sex cord stromal, germ cell and non-specified
ovarian cancers. Non-epithelial ovarian cancers only represent 10% of all ovarian
cancer, [6]while the remaining 90% of cancer comprises epithelial ovarian cancer
(EOC). EOC encompasses serous, transitional cell, mucinous, endometrioid, and clear
cell ovarian cancer [7]. EOC is generally divided into two subtypes. Type 1 EOC are
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considered more genetically stable, exhibit a slower tumor growth, and have disease
contained within the ovary upon initial presentation. These cancers respond well to
surgical intervention [7]. In contrast, type 2 EOC are characterized by an aggressive
growth rate and are usually detected at an advanced stage of IIIC. High grade serous
ovarian cancer (HGSOC) is the most common histological subtype of Type II EOC,
representing nearly three quarters of all patients diagnosed with ovarian cancer [5].
Seventy percent of the time, HGSOC is diagnosed at an advanced stage, leading to a
poor prognosis [5]. Therefore, efforts have been made to develop novel
prognostic/diagnostic methods and treatments to combat chemoresistance and improve
overall survival for HGSOC.

1.3 Current Ovarian Cancer Therapies
Many women who present with elevated tumor markers and abnormal imaging
typically proceed with primary debulking surgery. Initial surgery has three goals:
diagnosis, staging and cytoreduction. Diagnosis is important as needle biopsies are
not indicated for larger ovarian masses to prevent inadvertent spreading of the disease
[8]. If a patient presents with significant comorbidities, clinicians will favor
neoadjuvant chemotherapy over surgery. This approach minimizes surgical side
effects for patients, as the tumor will be reduced following chemotherapy [8].
For the past 20 years, standard of care for women diagnosed with EOC is a primary
frontline regimen of carboplatin and paclitaxel [9]. Carboplatin binds to DNA
forming a platinum adduct and causes cell death [10]. Paclitaxel’s mechanism of
action involves enhancing polymerization of tubulin, which stabilizes microtubules.
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This stabilization results in the protection of the microtubule polymer from
disassembly, and chromosomes are unable to achieve proper metaphase spindle
organization. Ultimately, cells are halted in the G2/M phase of the cell cycle [11]. The
overall response rate (ORR) for this combinational first line therapy is greater than
75%. However, the majority of patients experience a recurrence and progression of
disease. Once a recurrence occurs post-frontline therapy, the chemotherapy chosen for
the patient is based on the platinum-free interval (PFI), which represents the time
between the completion of the last platinum-based treatment and the detection of
relapse [12]. Patients that have a PFI of six months or less are considered to be
platinum-resistant, while patients that have a PFI greater than six months mark are
considered platinum-sensitive. This distinction determines the second-line
chemotherapy regimen used for the patient. [13]For platinum-sensitive patients
experiencing recurrence, doxil or gemcitabine is added to a platinum regimen [12].
Doxil, or pegalyated doxorubicin(PLD) is a polyethelyne-glycolate-coated liposomal
nanoparticle version of doxorubicin that exhibits enhanced drug delivery [14].
Doxorubicin is an antitumor antibiotic that promotes cell death by intercalation into
DNA, disrupting DNA repair mediated by topisomerase II, and generating free
radicals [15], Gemcitabeine is a pyrimidine antimetabolite that is inhibits tumor cell
progression through the G1/S phase, halting DNA synthesis [14]. While platinumsensitive patients undoubtedly survive longer than patients who are initially platinum
refractory, prognosis for these patients is still dismal. Platinum combinatorial
therapies with doxil and gemcitabine exhibit a progression-free survival (PFS) of only
11.3 and 8.6, respectively[16].

3

For platinum-resistant ovarian cancer, a non-platinum monotherapy is used with a
non-curative goal of toxicity management, as prognosis in this group is poor. Patients
in this group are frequently enrolled in clinical trials as a last attempt to control
disease [17]. Topotecan, which works through inhibition of topoisomerase I, is a
typical example of a salvage chemotherapy that is used in platinum resistant ovarian
cancer [18]. The response rate of patients to this treatment is only 12-18%, and PFS
is around 3-4 months[19,20]. Other typical monotherapies for platinum-resistant
second line EOC include doxil and bevacizumab [8]. Bevacizumab is a monoclonal
antibody against vascular endothelial growth factor (VEGF), a major regulator of
angiogenesis. Bevacizumab is approved in the recurrent setting, however it’s overall
efficacy continues to be studied clinically in different chemotherapy lines and in
combination with various treatment regimens [21]. While many large phase III trials
report an increase in PFS for patients, this response does not correlate with an
increased overall survival [21]. Other approved therapies in the maintenance setting
are PARP inhibitors. While these inhibitors are approved for all patients, within this
setting it has shown the most substantial benefit for patients who harbor the BRCA
mutation—about 20-25% of the patient population [22,23]. Current clinical trials for
EOC have largely focused on the immune checkpoint inhibition of programmed death
receptor (PD-1) and it’s ligand PD-L1, however clinical trial results have suggested
only a modest benefit [24]. Therefore, there is still a crucial treatment need for the
non-BRCA patient population.
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1.4 Detection Methods of EOC
Early detection for EOC is difficult as many symptoms reported by patients, such as
bloating and pelvic pain, are common symptoms of benign disease [25]. In addition,
the sensitivity and specificity of pelvic examinations for EOC screening purposes
within an asymptomatic population are poor. Therefore, diagnosis relies heavily on
tumor markers and radiologic imaging [25]. Currently, there has not been an official
recommendation for routine screening of asymptomatic women who are not high risk
for development of an ovarian malignancy [26].
Cancer antigen 125 (CA 125) is the most commonly used and validated tumor marker
for the detection of EOC [27]. However, recently there has been sufficient research
dedicated to an improvement of serum biomarkers for early detection of EOC. One
biomarker that represents such improvement is Human Epididymis Protein 4 (HE4),
which has been shown to have a higher specificity and comparable sensitivity to CA
125 [28]. From these results, the risk of ovarian malignancy algorithm (ROMA) was
established, which takes into account a woman’s menopausal status and incorporates
preoperative serum levels of CA 125 and HE4. The ROMA score exhibits both a
higher sensitivity and specificity than CA 125 alone [29]. As HE4 has been
extensively studied clinically, its prognostic capabilities have also begun to be
examined translationally.

1.5 Molecular Functions of HE4
HE4 is encoded by the Whey Acidic Protein (WAP) 4-disulphide core domain
(WFDC2) gene. The WFDC2 transcript was thought to be exclusively expressed in
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the epididymis and hence was originally proposed to be a specific marker for this
tissue type [30]. WFDC2 is a member of the WAP domain, which is a conserved
motif of 50 amino acids, including eight cysteine residues arranged as a 4-disulphide
core [31]. While WAP proteins can display a variety of functions, the most
comprehensively studied members of this family are the antiproteinases secretory
leukocyte protease inhibitor (SLPI) and elafin. In addition to antiproteinase activities,
both exhibit anti-inflammatory activities [32,33]. Due to the familial similarity of
HE4, it has been proposed to function similarly to SLPI and elafin; however, this role
has not been fully defined. In addition to HE4 overexpression in EOC tissue
compared to normal and benign ovarian tissues [29,34], it is also readily expressed in
the oral cavity, nasopharynx and respiratory tract [35]. It was suggested that HE4
functions in concert with other WAP domain family members to promote epithelial
host defenses of the lung, nasal, and oral cavity; supporting the claim that HE4 plays
a role in innate immune defenses [35]. HE4’s known molecular functions in EOC
pathogenesis, particularly its role in promotion of cell proliferation, chemoresistance,
metastasis and steroid biosynthesis, are comprehensively discussed in Chapter 2.

1.6 Problem Statement
Challenges in both treatment and diagnosis of patients has led to strong efforts to
elucidate new mechanisms of ovarian cancer pathology that can be used to develop
novel targeted therapies, which are so desperately needed for this patient population.
HE4 is a secretory protein that is overexpressed in EOC serum and tissue. Extensive
studies have also shown that HE4 promotes EOC growth and chemoresistance.
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However, the exact mechanisms of HE4 functions in EOC pathogenesis are not
completely understood. In addition, while HE4 was initially found to play a role in
innate immunity, its function in tumor immunity has yet to be defined. Therefore,
further investigation of HE4’s mechanistic promotion of tumorigenesis is an
important step to determine potential efficacy of a targeted anti-HE4 therapy for the
treatment of EOC.

The aim of this thesis research is to:
1. Determine genes most suppressed by HE4 in immune cell populations and
determine their involvement in muting the cytotoxic ability of immune cells
toward ovarian cancer cells.
2. Determine genes most induced by HE4 in immune cell populations and determine
their involvement in muting the cytotoxic ability of immune cells toward ovarian
cancer cells.
3. Establish the significance of HE4 regulated genes in EOC pathogenesis.
4. Define novel roles of proteins with an identified association with HE4 in EOC
pathogenesis.

1.7 Hypothesis
The overall driving hypothesis of this investigation is that HE4 represents a novel
therapeutic target due to its role in the promotion of EOC pathogenesis. While it is
known that HE4 has a profound role in EOC diagnosis, its therapeutics capabilities
have been largely undefined due to an incomplete identification of its signaling
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network in EOC. Although the precise mechanism is unknown, it has been established
that HE4 promotes tumorigenesis, chemoresistance, and metastasis in EOC. It has
been previously proposed that HE4 plays a role in innate immunity; however, its
immune functions in EOC have not been explored. The identification of novel genes
and proteins at a global level in both EOC and immune cells could aide in the
elucidation of a distinct HE4 signaling network. Thus, information obtained from
these studies will ultimately contribute to a comprehensive understanding of the
biological function of HE4 in EOC.
In manuscript I, subtractive hybridization revealed that SPP1, which encodes for the
protein OPN, was the gene most suppressed by HE4 expression in peripheral blood
mononuclear cells (PBMCs). Flow cytometry was employed to determine specific
immune cell populations within the PBMCs best characterized this relationship.
Downstream effectors of the suppressed gene responses were measured via ELISA
after stimulation with recombinant HE4. Ovarian cancer cells and PBMCs were then
co-cultured and treated with recombinant HE4 to determine how this treatment
compared to the effect of untreated PBMCs on ovarian cancer cell viability, cell
migration, and proliferation. Immunohistochemistry examined populations of OPN
positive T cells in human serous EOC tissue. Finally, HE4 siRNA was employed to
determine how its downregulation would affect apoptosis in ovarian cancer cells cocultured with PBMCs. Results were visualized by propidium iodide (PI) and Annexin
V staining.
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In manuscript II, subtractive hybridization determined that the gene that was most
induced by HE4 in peripheral blood mononuclear cells (PBMCs) was MKP-3, which
encodes for the protein DUSP6. Flow cytometry allowed for identification of specific
immune cell populations within the PBMCs that best characterize this relationship.
Flow cytometry and western blot examined levels of ERK activation when cells were
treated with recombinant HE4 and a small molecule DUSP6 inhibitor within specific
immune cell populations. Cells were treated with recombinant HE4 alone and in
combination with DUSP6 inhibition, and the following assessments were made: cell
viability, cell proliferation using Ki67 staining, and apoptosis by flow cytometry
detection of cells double positive for PI and annexin V. To verify effects the small
molecule inhibitor on DUSP6, cell viability, proliferation, and apoptosis experiments
were repeated in a co-culture devoid of the previously identified immune populations
responsible for upregulation of DUSP6 via HE4.
In manuscript III, the relationship between HE4 and DUSP6 was further elucidated in
ovarian cancer cells. To better define DUSP6’s role in EOC, immunohistochemistry
was performed to determine that levels of DUSP6 expression in patient tissue. Cell
viability of ovarian cancer cells was assessed following treatment with a small
molecule DUSP6 inhibitor alone and in combination with platinum-based
chemotherapeutics to determine synergistic effects. qPCR was used to determine how
DUSP6 inhibition alone and in combination with carboplatin or paclitaxel alters
expression of extracellular signal-regulated protein kinases (p-ERK) response genes.
HE4 and DUSP6 small interfering (si)RNA were employed to determine how
decreases of either factor affects the other DUSP6 gene and protein levels were
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assessed in HE4 overexpressing clones using qPCR and western blot.
In manuscript IV, Septin-2, a protein previously identified as strongly interacting with
HE4, was characterized in ovarian cancer for the first time. Immunohistochemistry
was employed to determine Septin-2 expression in EOC tissue. Two stable shRNA
knockout Septin-2 ovarian cell lines were developed and proliferation of the control
and knockout cell lines were compared by cell counting. Verification of the
knockdown was confirmed by quantitative polymerase chain reaction (qPCR) and
western blot. Finally, proteomics was utilized to determine global changes in protein
levels in the stable Septin-2 knockout cells. Gene ontology pathway analysis was also
performed to determine cellular proteins most affected by Septin-2 in EOC.
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2.1 Abstract
Human epididymis protein 4 (HE4) is an important clinical biomarker used for the
detection of epithelial ovarian cancer (EOC). While much is known about the
predictive power of HE4 clinically, less has been reported regarding its molecular role
in the progression of EOC. A deeper understanding of HE4’s mechanistic functions
may help contribute to the development of novel targeted therapies. Thus far, it has
been difficult to recommend HE4 as a therapeutic target owing to the fact that its role
in the progression of EOC has not been extensively evaluated. This review
summarizes what is collectively known about HE4 signaling and how it functions to
promote tumorigenesis, chemoresistance, and metastasis in EOC, with the goal of
providing valuable insights that will have the potential to aide in the development of
new HE4-targeted therapies.
2.2 Introduction
Approximately 22,280 new cases of epithelial ovarian cancer (EOC) are diagnosed
each year, resulting in 14,240 deaths annually in the United States (1). The 5-year
survival rate for stage III ovarian cancer is only 39% (1). These dire statistics are due
to the fact that the disease is frequently detected at an advanced stage, which
drastically impacts overall patient survival. Initially, many patients respond well to
first-line therapy that includes cytoreduction surgery and platinum-based treatment.
However, many patients experience a chemoresistant recurrence within the first 2
years following treatment (2). Therefore, there is an urgent need for tools to aid in the
early diagnosis of ovarian cancer when the disease is fundamentally curable, as well as
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improved treatment options for later stage disease.
Human epididymis protein 4 (HE4) is a secretory protein that is member of the whey
acidic protein domain family, bearing a conserved motif found in a number a protease
inhibitors (3). HE4 was initially suggested to be involved in the innate immune
defense of multiple epithelia and has also been found to function in epithelial host
defense (4). In ovarian tissue, HE4 is highly overexpressed in EOC compared normal
tissue (5, 6). Clinically, HE4 has been identified as a novel therapeutic biomarker for
EOC and has also proven useful in detection of recurrent disease (7) Serum HE4 level
predicts EOC with equal sensitivity to the established biomarker CA125 and is less
likely to be elevated in benign disease (5). A multicenter study led by our institution
established the FDA-approved Risk of Ovarian Malignancy Algorithm (ROMA),
which combines menopausal status and serum levels of both HE4 and CA125 to detect
and monitor EOC. ROMA demonstrates improved sensitivity and specificity over the
Risk of Malignancy Index that uses CA125 alone as a serum based biomarker (6).
Recently, it has been reported that HE4 can be detected in EOC patient urine,
indicating the possibility that it may be utilized as a non-invasive biomarker (8).
While HE4 has been well studied in the clinical setting, less is known regarding its
specific molecular and biological roles in EOC. Several studies have investigated its
effect on gene expression in EOC cells, as well as on events associated with
aggressive disease. This review will summarize HE4’s effect on cell proliferation and
tumor growth; invasion, migration, and adhesion; chemoresistance; and steroid
biosynthesis (Figure 1). Each section will detail associated pathways and factors that
are reported to be involved in these HE4-mediated effects, with the goal of revealing
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common themes in signaling pathways affected by HE4 and exposing gaps in our
knowledge of HE4 molecular and biological functions.
2.3 Review of Literature
Cell Proliferation and Tumor Growth
Within the past 5 years, a handful of in vitro and in vivo studies have begun to
examine HE4’s role in proliferation and tumor growth in EOC. A study by Wang et al.
examined the role of HE4 in cell proliferation and found that cells treated with
recombinant HE4 formed a statistically greater number of colonies compared with
control treated cells (9). Furthermore, cells stimulated with recombinant HE4
exhibited greater cell viability compared with respective controls. In another study by
Zhu et al. (10), proliferation rate in two different HE4-overexpressing cell lines was
significantly higher than in the control cells. Likewise, Zhu et al. (11) and Lee et al.
(12) determined that when HE4 was ablated via shRNA, cell proliferation decreased
accordingly. Kong et al. report conflicting results, stating that HE4 inhibits
proliferation in ovarian cells (13); however, no other studies support these claims,
necessitating further explanation to understand the implications of their results.
Several in vitro studies suggest that HE4 promotes proliferation through its
involvement in cell cycle regulation (11). Silencing of HE4 causes G0/G1 cell cycle
arrest and blocks the transition from the G1 to the S phase of the cell cycle.
Conversely, when cells are stimulated with recombinant HE4, the number of cells in
the G2/M phase is increased, while the number of cells in the G0/G1 phase is reduced
(9). These results indicate that HE4 may mediate the cell cycle by promoting the
G0/G1 transition. In addition, in vivo tumorigenicity studies using HE4 knockdown
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clones revealed a marked inhibition in the growth of ovarian tumors in nude mice (14),
while injection of HE4-overexpressing cells led to more aggressive tumor growth and
an overall higher tumor volume compared with controls (10, 15). Taken together,
results from numerous in vitro and in vivo studies provide compelling evidence that
HE4 plays a role in cell proliferation and the promotion of tumorigenesis. A full list of
factors associated with HE4-mediated cell proliferation and tumor growth can be
found in Table 1A and is outlined in greater detail below.

Associated Pathways and Factors-Cell Proliferation and Tumor Growth
Human epididymis protein 4 has been connected to several oncogenic signaling
cascades that play key roles in ovarian cancer progression, including the PI3K/AKT
pathway, HIF1α, and ERK/mitogen-activated protein kinase (MAPK) signaling.
Evidence of HE4’s effect on activation of each of these pathways is discussed below.

Protein Kinase B Signaling
AKT has been established as a strong promoter of tumorigenesis, and the PI3K/AKT
pathway is one of the most commonly hyperactivated pathways in many types of
human cancers (16). Its diverse signaling regulates proliferation, growth, survival,
motility, angiogenesis, and glucose metabolism (17). HE4-overexpressing OVCAR3
ovarian cancer cells were found to have a marked increase in activation of protein
kinase B (AKT) compared with control cells, while HE4 knockdown in OVCAR3
cells reduced AKT activation (12). Moreover, it was found that HE4-overexpressing
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SKOV3 clones had naturally higher gene levels of AKT3 compared with the nullvector control (18), bolstering the claim that HE4 affects the PI3K/AKT pathway.

Hypoxia-Inducible Factor-1 Alpha (HIF1α)
Adaptation of malignant cells to hypoxic conditions is a key step in the promotion of
tumorigenesis and angiogenesis (19–21), a process that is regulated by the
transcription factor HIF1α. Co-immunoprecipitation revealed an interaction between
HIF1α and HE4 in HE4-overexpressing SKOV3 xenografts. There was also strong
colocalization of HE4 and HIF1α in SKOV3 ovarian xenograft tissue. In addition,
when SKOV3 cells were treated with HIF1α siRNA or 2-methoxyestradiol (a HIF1α
inhibitor), there was a marked decrease in HE4 protein levels (15). It is important to
note that 2-methoxyestradiol is not a specific HIF1α inhibitor as it primarily causes the
depolymerization of microtubules, which in turn prevents HIF1α expression (22).
Thus, the specificity of the effect of HIF1α inhibition on HE4 levels may require
further investigation. Although the exact mechanism and significance of the HE4HIF1α interaction is not understood, this evidence suggests that HE4 could play a role
in regulating HIF1α functions in angiogenesis.

MAPK Signaling
The MAPK pathway is composed of a family of conserved kinases that mediate
essential cellular processes such as migration, growth, proliferation, differentiation,
and apoptosis (23). The extracellular signal-regulated kinase (ERK) pathway is the
best characterized of all MAPK pathways and is deregulated in approximately one-
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third of all cancers. Several studies have shown activation of ERK in response to HE4
treatment or overexpression, or suppression of ERK phosphorylation in response to
HE4 knockdown (11,12,18). Using microarray analysis, Zhu et al. determined that
seven genes involved in the MAPK pathway (CHUK, GADD45A, IL1A, RPS6KA1,
HSPA1B, DUSP1, and JUND) were differentially regulated in response to HE4
overexpression in ES-2 cells (10).
Activation of the MAPK/ERK pathway occurs through EGF binding of its membrane
bound receptor, EGFR (24). Using co-immunoprecipitation studies in SKOV3 cells,
Moore et al. found that HE4 interacts with EGFR, with a greater degree of
immunoprecipitation seen in HE4-overexpressing clones than wild-type cells (15).
Furthermore, ovarian xenograft tissue showed colocalization of HE4 and EGFR. In
addition, when SKOV3 and OVCAR8 cells were stimulated with growth factors EGF,
VEGF, and Insulin, nuclear localization of HE4 was significantly increased. Finally,
when EGF was repressed by the small molecule inhibitor Iressa, relative intensity of
HE4 staining was decreased in ovarian cancer cell lines. Collectively, these results
provide several layers of evidence that HE4 is tied to growth factor signaling and the
MAPK/ERK pathway, although further research is needed to elucidate the precise
mechanisms involved.

HE4’s Role in Proliferation in Other Cancers
Human epididymis protein 4 has been investigated as a putative biomarker in
endometrial (25–39), lung (40–52), breast (53, 54), pancreatic (55, 56), and gastric
cancer (57). While the majority of these studies examine the value of HE4 as a clinical
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biomarker for detecting and monitoring disease, one study investigated the molecular
mechanisms of HE4 in pancreatic and endometrial cancer. Lu et al. stimulated both
pancreatic and endometrial cancer cell lines with recombinant HE4 and found that cell
viability, cell growth, and DNA synthesis was increased prominently in both cancer
types (56). They also report that HE4 upregulates gene expression of proliferating cell
nuclear antigen (PCNA) and downregulates p21 in both cancer cell lines in a dose
dependent manner. PCNA, which is expressed in the late G1/S phase of the cell cycle,
is required for DNA repair, replication, cell proliferation, and cell cycle progression
(58), while p21 is an important effector of tumor suppressor pathways by promoting
cell cycle arrest. Specifically, p21 is able to facilitate p53-dependent G1 growth arrest
(59). Therefore, results from this study highlight HE4’s role in proliferation in both
pancreatic and endometrial cancer and lend support to similar evidence from studies
published on EOC.

Invasion, Migration, and Adhesion
Several studies have associated HE4 with metastatic properties, including invasion,
migration, and adhesion of ovarian cancer cells. Lu et al. found that adhesion to a
fibronectin substrate was twofold greater in SKOV3 cells overexpressing HE4 than in
mock cells. In addition, a transwell migration assay demonstrated that the HE4overexpressing clones had a 1.8-fold greater migration capacity than mock transfected
cells. By contrast, immunofluorescence analysis showed that HE4 knockout clones
displayed inhibited cell-spreading ability in a statistically significant fashion compared
with respective controls. Furthermore, cell invasion, proliferation, and migration were
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significantly decreased in these clones (14). In agreement with this study, Ribeiro et
al. also found that OVCAR8 ovarian cells treated with recombinant HE4 exhibited
2.07-fold greater invasion capacity and 1.29-fold greater adhesion to a fibronectin
matrix compared with untreated controls. Interestingly, there was no change in
adhesion to collagen I, IV, laminin I, and fibrinogen matrices, suggesting that HE4 has
a specific effect on fibronectin adhesion. Haptotaxis toward a fibronectin substrate
also was increased in the ovarian cancer cells treated with recombinant HE4 by 1.72fold (60).
Zhu et al. used wound healing and transwell invasion assays to show that HE4overexpressing ES-2 and CaOV3 cells possess enhanced cell migration and invasion
capacities. In addition, in vivo tail vein injection of HE4-overexpressing ES-2 cells
into nude mice resulted in significantly more metastatic lung nodules than mock
transfected cells (10). Using the same ovarian cancer cell lines, Zhuang et al. report
the importance of HE4 interaction with annexin II (ANXA2) to promote invasion and
migration in vitro and metastasis in vivo (61). Finally, Zou et al. found that
knockdown of HE4 in SKOV3.ip1 cells inhibited migration and invasion (62). Taken
together, these studies strongly suggest that HE4 plays a prominent role in the
promotion of ovarian cancer metastasis. A full list of factors associated with HE4mediated invasion, migration, and adhesion can be found in Table 1B and is outlined
in greater detail below.
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Associated Pathways and Factors—Invasion, Migration, and Adhesion
Human epididymis protein 4 appears to interact with numerous molecular pathways
that promote metastasis in ovarian cancer. However, it is still not entirely known how
HE4 affects signaling pathways and gene expression signatures to promote invasion,
migration, and adhesion of ovarian cancer cells. Following is a summary of HE4mediated molecular pathways that are involved in metastatic events in EOC.

Matrix Metalloproteinases (MMPs)
Human epididymis protein 4 has been associated with MMPs MMP-9 and MMP-2,
and Cathepsin B. MMPs are a family of zinc-dependent endopeptidases that are vital
for the remodeling of the extracellular matrix (63). They are expressed in almost all
types of cancers and are responsible for stimulating angiogenesis, tumor growth, and
metastasis (64, 65). Cathepsin B is a lysosomal cysteine protease that has been linked
to cancer progression (66), specifically in signaling pathways related to angiogenesis
(67). In addition, it can promote MMP activity by degrading MMP inhibitors (68).
Interestingly, silencing of HE4 in ovarian cancer cells led to a decrease in protein
levels of MMP-9, MMP-2, and Cathepsin B, suggesting these factors may be involved
in HE4-mediated tumor promoting effects (11).

Interleukin-1 alpha (ILIA)
Interleukin-1 alpha is a pro-inflammatory cytokine that is involved in angiogenesis
and metastasis. ILIA can directly stimulate the synthesis of VEGF (69) and
fibroblastic pro matrix metallic proteinase I (70, 71). IL1A causes resistance to EGFR
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inhibitors in both colon and head and neck cancers (72, 73). IL1A was also found to
be differentially expressed in three separate microarray studies involving HE4. In two
microarrays, IL1A levels positively associated with HE4 levels (10, 74), while in one
study their levels were inversely associated (18). While there may be some ambiguity
as to how HE4 and IL1A are mechanistically linked, the consistent connection
between IL1A with HE4 merits further investigation.

Extracellular Matrix Proteins
Integrins are a family of transmembrane proteins that are vital to ECM adhesion and
play important roles in wound healing as well as the pathogenesis of cancer (75–77).
Integrin β5 (ITGβ5) gene expression was differentially regulated by HE4 in ES-2 and
CaOV3 cells, which was confirmed by positive correlation of ITGB5 and HE4
staining in paraffin embedded ovarian tissue samples (10). This finding suggests that
integrin signaling is one mechanism by which HE4 can promote increased adhesion of
ovarian cancer cells. However, further research is needed to clarify the mechanisms
involved.
In addition to ITGβ5, three other genes related to ECM modeling—syndecan 1
(SDC1), collagen type 1 alpha 1 (COL1A1), and dystroglycan 1 (DAG1)—were more
highly expressed in cells overexpressing HE4 and were downregulated in cells with
HE4 knockdown (10). SDC1, also known as CD138, is an essential cell surface
adhesion molecule that is responsible for maintaining cell morphology and
interactions within the surrounding microenvironment (78). Loss of SCD1 in cancer
cells is associated with reduced ECM adhesion and enhanced invasion and cell
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motility (79). Another ECM gene found to be affected by HE4 expression levels,
COL1A1, is a crucial component of the ECM as it supports cartilage, bone, and tendon
tissues in the body and also functions to maintain the rigidity and elasticity of tissues
(80, 81). COL1A1 plays an important role in cancer, since tumor cells that express
COL1A1 are able to dissociate from their surrounding stromal components, which is
essential for tumor growth (81). The final ECM gene found to be affected by HE4 is
DAG1, which is a cell adhesion molecule that plays a key role basement membrane
assembly (82), muscle integrity (83), and the maintenance of basolateral cell adhesion
in numerous epithelial tissues (84). Loss of DAG1 is associated with cancer
progression (85). Taken together, these results show that HE4 is strongly
interconnected with ECM related proteins, specifically those involved in the ITGβ5
signaling pathway.
Our lab has also determined that HE4 regulates several components of the
extracellular matrix (60). We performed microarray analyses comparing untreated
OVCAR8 wild-type cells to recombinant HE4 treated cells, and OVCAR8 cells
overexpressing HE4 to null-vector control cells. Serpin peptidase inhibitor, member 2
(SERPINB2), gremlin 1 (GREM1), laminin-β3 (LAMB3), laminin-γ2 (LAMC2),
fibroblast growth factor 5 (FGF5), and tenascin C (TNC) were all found to be
significantly upregulated upon treatment with recombinant HE4. These genes encode
for extracellular matrix proteins that promote cell migration and adhesion (60).
Specifically, we found that HE4 upregulates LAMC2 and LAMB3 proteins in a timedependent manner, and this increase of both factors in turn leads to an increase in
laminin-332 levels (60). Laminin-332, a heterotrimer composed of LAMC2, LAMB3,
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and LAMA2, is an important component of the basement membrane in epithelial
tissue. Abnormal increases in its levels have been shown to promote increased
invasion in cancers (86). Further evidence suggested involvement of the FAK pathway
in these events. In addition, activation of matriptase, a serine protease responsible for
cleaving laminin-332 in its β chain and regulating its effects on metastatic properties,
increased upon in vitro exposure to recombinant HE4 (60). This study provides
compelling evidence that HE4 is involved in basement membrane invasion and
adhesion.

Lewis y Antigen
Human epididymis protein 4 undergoes glycosylation before it is secreted by ovarian
cells (87), prompting Zhuang et al. to examine the relationship between HE4
glycosylation status and metastatic properties. Lewis y antigen is a glycosyl antigen
that is overexpressed in ovarian cancer and has been associated with chemoresistance
and poor prognosis (88–97). They determined that Lewis y antigen was present in
HE4 from benign and malignant ovarian tissues, in vitro cancer cells, and culture
medium. HE4 from ovarian cancer samples contained higher levels of Lewis y antigen
than HE4 from benign tissues, and their expression co-localized in ovarian cancer
tissue (98). Furthermore, when Lewis y antigen was over expressed, it promoted HE4mediated invasion and metastasis in ovarian cancer cell lines. Conversely, when Lewis
y antigen was blocked, the invasive and metastatic properties of HE4 were
significantly decreased (99). Interestingly, overexpression of Lewis y antigen
increased tyrosine phosphorylation of EGFR and HER/neu, which promoted cell
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proliferation through the PI3K/Akt and Raf/MEK/MAPK pathways (100). Thus, it
appears that Lewis y antigen and HE4 affect similar signaling pathways that promote
tumor growth and malignancy (101). Taken together, these results show that Lewis y
antigen could be a potential therapeutic target to decrease HE4 function in the
treatment of EOC.

Heparin Cofactor II (HCII)
SERPIND1 encodes for the protein HCII, which is a serum glycoprotein and protease
inhibitor (102). A study in non-small cell lung cancer (NSCLC) showed that HCII
promotes cell motility, invasion, and filopodium dynamics through the PI3K/AKT
pathway. High HCII expression in NSCLC tissue correlated to an increased recurrence
rate and shorter overall survival (103). Furthermore, its levels were upregulated in
metastatic brain cell lines compared with non-metastatic parental lines, suggesting an
involvement of SERPIND1 in metastatic functions (104). Results from a microarray
study by Zhu et al. showed that SERPIND1 was upregulated in HE4-overexpressing
cells and conversely downregulated in HE4 knockdown cells. These results were
validated via qPCR and immunohistochemistry. In addition, they found that 37/50
ovarian cancer samples showed positive expression of both SERPIND1 and HE4, and
Spearman correlation analysis confirmed that HE4 and SERPIND1 were positively
correlated. Finally, Kaplan–Meier analysis revealed that patients with high levels of
HE4 and SERPIND1 had a worse prognosis (74). While these data strongly suggest a
connection between HE4 and SERPIND1, which may be related to their roles in
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promoting ovarian cancer metastasis, further study of the association between these
two proteins is required.

Annexin II
Annexin II is a calcium-dependent, phospholipid-binding protein that is overexpressed
in a variety of cancers and is involved in angiogenesis, proliferation, apoptosis, cell
migration, invasion, and adhesion (105). High levels of Annexin II activate MAPK
signaling, which in turn promotes tumor proliferation (106), invasion (107), and
metastasis (108). Zhuang et al. employed mass spectrometry and coimmunoprecipitation to identify Annexin II (ANXA2) as a strong HE4 interacting
partner (61). This binding promoted invasion and metastasis in ES-2 and CaOV3
ovarian cancer cells. HE4 and ANXA2 gene expression levels were found to be codependent, and examination of EOC tissue revealed that both HE4 and Annexin II
levels were increased in malignant phenotypes compared with benign and normal
ovarian tissues. Both proteins were also more highly expressed in tissues from patients
with lymph node metastases than those without. Downregulation of HE4 was found to
decrease expression of MKNK2 (MAP kinase-interacting serine/threonine-protein
kinase 2) and LAMB2 (laminin, beta-2), two factors associated with MAPK and focal
adhesion signaling pathways. When HE4 protein was supplemented, this effect was
reversed. Collectively, these results show that HE4 interaction with Annexin II to
activate MAPK and focal adhesion signaling is one mechanism by which HE4 may
promote ovarian cancer metastasis.
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Chemoresistance
Several studies show that HE4 is associated with chemoresistance clinically. The
addition of HE4 serum levels in the ROMA score better predicts platinum resistance in
patients than CA125 alone (15). Angioli et al. found that HE4 was able to predict
chemotherapy response in EOC patients undergoing first-line therapy (109). In
addition, higher levels of serum HE4 are reported in women who are resistant to firstline chemotherapy (110). Finally, higher HE4 levels inversely correlate with clinical
outcome (111), optimal cytoreduction (112), progression free survival (113), and
overall survival (15, 113). While the mechanism underlying HE4’s contribution to
chemoresistance has not been established fully, a few studies have begun to delineate
HE4’s role in this process. A full list of factors associated with HE4-mediated
chemoresistance can be found in Table 1C and is outlined in detail below.

Associated Pathways and Factors—Chemoresistance
Antiapoptotic Gene Expression
A study performed in our lab by Ribeiro et al. determined that HE4 overexpression
promotes collateral chemoresistance to both cisplatin and paclitaxel in SKOV3 and
OVCAR8 cells (18). Conversely, CRISPR/Cas9 mediated knockdown of HE4 in
SKOV3 cells overexpressing HE4 partially reversed their chemoresistance.
Microarray analysis revealed suppression of cisplatin-induced early growth response 1
(EGR1) gene expression in HE4-overexpressing SKOV3 cells compared with null
vector-transfected cells (18). EGR1 is a transcription factor that regulates apoptosis,
proliferation, and differentiation through regulating expression of genes such as p53,
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BCL2, PTEN, IGF2, PDGF, VEGF, TGFB1, and TNF (114, 115). EGR1 expression is
influenced by MAPK signaling, including phospho-ERK and phospho-p38 (115).
Ribeiro et al. found that p38 was strongly activated in SKOV3 null vector-transfected
cells treated with cisplatin, while its activation was suppressed in HE4-overexpressing
clones (18), suggesting that HE4-mediated chemoresistance may involve MAPK
signaling.
Similarly, a study by Wang et al. showed that HE4 represses carboplatin-induced
apoptosis in vitro. Recombinant HE4 caused an increase in expression of antiapoptotic
protein B-cell lymphoma 2 (BCL-2) and a decrease in expression of pro-apoptotic Bax
(Bcl-2 associated X protein) in SKOV3 cells treated with carboplatin (9). This
decrease in the Bax/Bcl-2 ratio, in addition to the suppression of EGR1 when HE4 is
overexpressed, may contribute to the overall decrease in pro-apoptotic factors that
leads to chemoresistance in EOC.

Microtubule Stabilization
Microtubule-associated protein tau, which has been associated with paclitaxel
resistance in ovarian (116), breast (117), and gastric cancer (118), was upregulated in
SKOV3 cells overexpressing HE4 compared with null-vector cells (18). In addition,
HE4-overexpressing cells were found to express significantly higher levels of SEPT3
(Septin 3) mRNA compared with null-vector controls (18). Septins are a family of
conserved GTP binding proteins that are associated with microtubules and actin
filaments and have an important role in cytoskeletal organization (119). Furthermore,
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recombinant HE4 treatment of SKOV3 cells increased β-tubulin levels, indicating that
HE4 might promote microtubule stability, leading to paclitaxel resistance.

Kinase Signaling Pathways
Human epididymis protein 4 knockdown has also been shown to lead to a reduction in
cell growth and the resensitization of ovarian cancer cells to both cisplatin and
paclitaxel (12). Lee et al. found that this effect was due to corresponding decreases of
ERK and AKT in HE4 knockouts. Activation of these pathways suppresses apoptotic
signaling in tumors, suggesting that HE4’s regulation of these pathways may be an
important mechanism of chemoresistance (120).

Steroid Biosynthesis
Evidence suggests an association between sex steroids and EOC pathogenesis, which
is explained by processes that take place during the menstrual cycle. The ovarian
surface epithelium (OSE) plays a critical role in ovulation and postovulatory wound
repair. During the menstrual cycle, the OSE proliferates during the pro-estrus/estrus
transition. After, ovulation the proliferation rate decreases (121). It is hypothesized
that when the OSE is repeatedly exposed to high doses of luteinizing hormone and
follicle stimulating hormone during the menstrual cycle, this can promote cell
proliferation and increase the likelihood of tumor growth over time (121).
Furthermore, epidemiological data have suggested that ovarian cancer progression,
pathogenesis, and etiology are highly dependent on the activity of estrogens (121), and
numerous experimental studies have demonstrated the promotive effect of estrogens
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on ovarian tumors in mice and human EOC cell lines (122). However, activation of
diverse oncogenic pathways in EOC may lead to the eventual downregulation of ERα
levels and the overall decrease in ERα related signaling in ovarian cancers, rendering
them resistant to anti-estrogen therapies (122). Some evidence exists that HE4 may be
involved in this process by regulating steroid signaling in EOC. A full list of factors
associated with HE4-mediated steroid biosynthesis can be found in Table 1D and is
outlined in detail below.

Steroid Biosynthesis Gene Expression
Two separate microarray pathway analyses identified steroid biosynthesis as a
pathway affected by HE4 (10, 74). Important genes that were differentially expressed
between HE4-overexpressing and HE4 knockdown cell lines were Forkhead box
protein A2 (FOXA2) (74), squalene monooygenase (SQLE), 7-dehydrocholesterol
reductase (DHCR7), 24-dehydrocholesterol (DHCR24), and sterol-4-alphacarboxylate-3-dehydrogenase (NSDHL) (10). FOXA2, a transcription factor required
for normal metabolism (123), promotes cell proliferation, maintains cancer stem cells,
and is associated with a higher rate of relapse in triple-negative breast cancer (124).
Another gene differentially regulated by HE4, SQLE, is an enzyme required in the
later stages of cholesterol synthesis (125). Out of 22 cancer types, SQLE copy
number-driven gene expression was highest in breast, ovarian and colorectal cancer
(125). Also affected by HE4 levels was DHCR7, one of the terminal enzymes
involved in the production of cholesterol from 7-dehydrocholesterol (7DHC). DHCR7
was found to be an important regulatory determinate between cholesterol and vitamin
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synthesis, as cholesterol is able to accelerate the proteasomal degradation of DHCR7,
which can result in the accumulation of 7DHC and an increased production of vitamin
D (126). DHCR24, which was also affected by modulation of HE4 levels, is another
enzyme in the cholesterol biosynthesis pathway (127). It interacts physically and
functionally with DHCR7 (128) and has a number of different cellular functions
including anti-inflammatory and antiapoptotic functions, as well as regulation of
oxidative stress and cell differentiation (129). DHCR24 has also been proposed to be
involved in tumor progression, as its deregulation has been linked to prostate, ovarian,
and urothelial carcinomas (127).
Finally, NSDHL is also involved in cholesterol biosynthesis and produces metabolites
that are essential in the conversion of squalene to cholesterol (130). Interestingly,
NSLD1 was found to have a role in the control of signaling, vesicular trafficking, and
degradation of EGFR and its dimerization partners ERBB2 and ERBB3. A study by
Sukhanova et al. showed that NSLD1 knockout in vivo leads to a reduction in EGFR
activation (131). The results from these microarrays show that modulating HE4 levels
results in differential expression of several genes involved in steroid biosynthesis—
especially cholesterol—suggesting that HE4 may affect tumor metabolism and
ultimately contribute to tumorigenesis.

Estrogen Signaling
In support of the above described pathway analyses, two other studies have shown that
HE4 interacts with steroid signaling, specifically estrogen signaling. Lokich et al.
showed that ERα expression was reduced in HE4-overexpressing SKOV3 cells,
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resulting in increased resistance to tamoxifen and fulvestrant compared with wild-type
cells (132). 5-Methylcytosine (5-MC), a methylated form of the DNA base cytosine, is
one of the most prominently identified epigenetic modifications, and can cause
suppression of ERα gene expression. Deregulation of DNA methylation can result in
abnormal gene expression and tumorigenesis (133, 134). Lokich et al. found that 5MC was readily detected in SKOV3 wild-type and null-vector cells but not in HE4overexpressing clones, suggesting that HE4 overexpression may have an effect on
epigenetic modifications (132). However, methylation of the ERα gene was not
specifically examined in this study. It is unclear whether HE4 overexpression would
promote increased methylation at the ERα promoter region (even with the presence of
global demethylation), which would be expected given the reported suppression of
ERα in this study.
Interestingly, Chen et al. reported that when HO8910 ovarian cancer cells were
stimulated with estradiol (E2), there was an increase in the expression of HE4 at the
mRNA and protein level. This effect was not observed in estrogen-insensitive SKOV3
cells; however, when HE4 was knocked down in SKOV3 cells, their proliferative
response to estrogen was restored (135). Collectively with the results shown by Lokich
et al, this study suggests that HE4 works to suppress estrogen signaling in ovarian
cancer cells, which can contribute to resistance to anti-estrogen therapies. Conversely,
it appears that estradiol promotes HE4 expression in estrogen-responsive cells, which
could indicate a role for HE4 in the initial tumor promoting effects of estrogen.
Further clarification of the effect of HE4 on estrogen signaling may be useful in
improving implementation of anti-estrogen based therapies.
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2.4 Conclusion
Ovarian cancer is an extremely deadly disease owing to the fact that patients are
typically diagnosed at a late stage. Initially, patients respond well to frontline platinum
therapy; however, a majority of tumors recur, and the initial chemosensitivity
eventually gives way to a broad chemoresistance (136). Available detection methods
have improved in recent years with the discovery of HE4 as a diagnostic and
prognostic biomarker. However, there has yet to be a breakthrough targeted therapy to
combat EOC. While PARP inhibitors are used in the maintenance setting for all
patients, this therapy has most significantly benefited BRCA-positive patients, who
comprise only 20–25% of patients (137, 138). In addition, inhibitors of immune
checkpoints, such as programmed death ligand-1 have demonstrated modest benefit in
clinical trials for ovarian cancer (139). Therefore, there is still a crucial need for novel
targeted EOC treatments.
Although HE4 is well established as a clinical biomarker for ovarian cancer, it has
been largely understudied for its therapeutic targeting potential. However, ongoing
research continues to support that HE4 is profoundly involved in the pathogenesis of
EOC. The individual studies mentioned in this review provide evidence that HE4
promotes EOC progression through pathways associated with cell proliferation, tumor
growth, metastasis, chemoresistance, and steroid biosynthesis. These pathways, along
with specific genes that have been shown to be associated with HE4, are summarized
in Table 1. This compilation of HE4 regulated factors and pathways will serve as a
starting point for scientists to further elucidate specific mechanisms by which HE4
ultimately drives tumorigenesis. In addition, a comprehensive summary of clinical, in
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vivo, and in vitro studies related to each facet of EOC progression and HE4 can be
seen in Figure 1. This diagram highlights the progress that has been made to establish
HE4 as an attractive therapeutic target, while simultaneously denoting areas of
research that are still lacking. The results discussed here suggest that inhibition of
HE4 via a neutralizing antibody or small molecule inhibitor could provide viable
treatment options for patients in dire need of more effective therapies.
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Figure 2.1 Graphical Representation of clinical, in vivo and in vitro studies completed
relating to HE4 and EOC.

56

Table 2.1 Summary of factors associated with HE4 in EOC
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I.1 Abstract
Ovarian tumors are known to suppress immunosurveillance and promote immune
escape. Here, we examine the role of the secretory glycoprotein HE4 in ovarian cancer
immune evasion. Through modified subtractive hybridization analyses of human
peripheral blood mononuclear cells (PBMCs), we have characterized gene targets of
HE4 and established a preliminary mechanism of HE4-mediated immune failure in
ovarian tumors. Upon exposure of PBMCs to recombinant human HE4 in vitro,
osteopontin (OPN) emerged as the most suppressed gene, while DUSP6 was the most
upregulated gene. SKOV3, a human ovarian carcinoma cell line, exhibited enhanced
proliferation in conditioned media from HE4-exposed PBMCs, and this effect was
attenuated by the addition of recombinant OPN or OPN-inducible cytokines (IL-12
and IFN-). Additionally, upon co-culture with PBMCs, HE4-silenced SKOV3 cells
were more susceptible to cytotoxic cell death. The relationship between HE4 and
OPN was further reinforced through analysis of serous ovarian cancer patient samples.
In these biopsy specimens, the number of OPN+ T cells correlates positively with
progression free survival (PFS) and inversely with serum HE4 level. Taken together,
these findings show that HE4 enhances ovarian cancer tumorigenesis by
compromising OPN-mediated T cell activation.
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I.2 Introduction
Human epididymis protein 4 (HE4) is a member of the whey acidic domain family of
proteins (WAP), which are generally regarded as protease inhibitors (1-3). HE4 was
first identified in the male reproductive tract but has since been found in select other
tissues, such as the kidney, female reproductive tract, breast, and lungs (4,5). In
addition, it is highly overexpressed in several human malignancies, including ovarian
and endometrial cancer (5-8). HE4’s role in normal and malignant tissue is still
unclear; however, as a known negative prognostic factor in women with epithelial
ovarian cancer, its serum levels correlate with chemoresistance and reduced survival
(9-11). Our previous work with HE4 has led to the development of a USFDA
approved biomarker tool for evaluation of pelvic masses, coined the Risk of Ovarian
Malignancy Algorithm (ROMA) (12-15). The ROMA score incorporates HE4, CA125, and menopausal status into a calculation to estimate ovarian cancer risk. As a
biomarker, HE4 detection and monitoring is already improving patient care. However,
it is imperative that we learn more about its function in order to better understand
ovarian tumorigenesis and ultimately develop effective therapies for this fatal cancer.
In this present study, we begin to elucidate HE4’s role in the interplay between tumor
cells and the immune system. We generated cDNA-subtracted libraries of HE4 treated
peripheral blood mononuclear cells (PBMCs) and employed a modified subtractive
hybridization method to identify differentially expressed genes. This strategy
identified osteopontin (OPN) as one of the most prominently suppressed targets in
PBMCs following HE4 treatment. OPN is a secretory glycosylated phosphoprotein
encoded by the gene SPP1. OPN contains an arginine-glycine-aspartate (RGD)
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sequence that—via interactions with integrin family members or CD44—triggers
downstream signaling events and relays early cell-mediated immune responses (1618). We observed that HE4-induced OPN suppression mitigated the cytotoxicity of
PBMCs against cultured human ovarian cancer cells in vitro. Further, the expression
levels of OPN in stromal infiltrating T cells in biopsy samples from serous ovarian
cancer patients showed direct association with patient progression free survival (PFS).
Together, our data demonstrates that HE4 inhibits the immune function of PBMCs,
most prominently T cells, via suppression of OPN production.

I.3 Materials and methods
Subtractive hybridization and TA-cloning.
Primary human PBMCs were obtained under the auspices of Women & Infants
Hospital IRB approval from a single volunteer. Approximately 5 x 107 of PBMCs
were obtained from 40 mL of heparinized total blood. The cells were suspended in 5
mL of serum free RPMI1640 medium (#31800022; Invitrogen, Carlsbad, CA, USA)
and incubated with or without 0.01 g / mL (approximately 270 pM) of rHE4
(MBS717359; MyBiosource, San Diego, CA, USA) for 6 hours, and total RNA was
isolated using TRIzol reagent (Invitrogen). The dose of HE4 (0.01 g / mL, 270 pM)
was chosen as a comparable concentration to serum levels in patients with various
types of ovarian tumors (19). Around 300 g of total RNA was isolated in this scale of
preparation. The RNA was stored at -80 degrees until messenger RNA (mRNA)
isolation. Blood draws were repeated at a minimum of 7-day intervals until the amount
of total RNA collected reached 1 mg. Next, mRNA was purified using oligo dT coated
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magnetic beads (Takara-Clontech, Mountain View, CA, USA). Approximately 10 g
of mRNA was isolated from the 1 mg of total RNA, from which subtractive cDNA
libraries were constructed using PCR-SelectTM cDNA Subtraction Kit (TakaraClontech, Mountain View, CA, USA), following the manufacturer’s instructions.
Briefly, the tester and driver cDNAs are synthesized from poly A+ RNA generated
from control and HE4 treated PBMCs. The tester and driver cDNAs are each digested
with a restriction enzyme, Rsa I, to yield shorter, blunt-ended molecules. The tester
cDNA is then subdivided into two portions, and each is ligated with a different cDNA
adaptor. The ends of the adaptor do not contain a phosphate group, so only one strand
of each adaptor attaches to the 5' ends of the cDNA. The two adaptors have stretches
of identical sequence to allow annealing of the PCR primer once the recessed ends
have been filled in. The differentially expressed genes were identified through two
steps of hybridizations followed by two steps of PCR. The PCR products of the
differentially expressed genes were cloned into a pUC19-TA vector. The clones
containing the inserts were selected by blue/white selection and were amplified by
colony PCR using M13 primers.

Cell culture
The human ovarian cancer cell lines SKOV3 and OVCAR8 were obtained from
ATCC (Manassas, VA, USA). RPMI1640 (#31800022; Invitrogen) and DMEM
supplemented with 1.0 mM of sodium pyruvate (#31600034; Invitrogen) were used
for culturing PBMC and SKOV3, respectively. Conditioned media was obtained from
24-hour PBMC culture with or without 0.01 g / mL (270 pM) of rHE4. Residual
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rHE4 in the conditioned media was deprived as follows. Five mLs of media was
incubated with 10 g (100 L) of anti-human HE4 antibody (sc-293473; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 hour at 4 degrees. Then, 100 L packed
volume of protein G coated sepharose beads (GE Healthcare Life Science, Pittsburg,
PA, USA) was added and incubated for 4 hours at 4 degrees. After the incubation, the
sepharose beads were removed by centrifugation and the supernatants were processed
through a sterile 0.2 m pore syringe filter. The conditioned media were used without
any dilution. For the cell-mediated cytotoxicity assay, 2 x 105 target cells (SO or
shHE4 transfected SKOV3) were seeded in each well of 6-well plates, and then were
incubated overnight with complete media. The next day, cells were placed in serum
free media for another overnight incubation to induce quiescence, and then 1 x 107 of
the effector cells (PBMC) mixed with propidium iodide (Invitrogen) were added to
each well. Some of the wells contained 5 pg / mL of rIL-12 (219-IL-005; R&D
Systems, Minneapolis, MN, USA), 20 pg / mL of rIFN- (SRP3058; Sigma-Aldrich,
St. Louis, MO, USA) or 0.05 g / mL of rHE4 (ab132299; Abcam) in combinations as
indicated in Figure 4 (lower panel). The ovarian cancer cell lines were
morphologically normal and kept growing up to 72 hours in serum deprived DMEM.
In order to avoid unexpected effects of unknown constituents in the serum, all
experiments were performed under serum free condition. shRNA for human HE4
(TR318721; Origene, Minneapolis, MN, USA) were transfected into SKOV3 using
Lipofectamine 2000TM (Invitrogen) following the manufacturer’s instructions. In other
cases, cells were treated with 20 pg / mL recombinant OPN (ab92964; Abcam) or 0.01
g / mL rHE4.
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Quantitative Real-Time PCR
RNA was isolated from PBMCs of healthy donors using TRIzol (Invitrogen)
according to the manufacturer’s instructions. cDNA was synthesized using
SuperScript III reverse transcriptase (Invitrogen). qPCR was performed using Premix
Ex-TaqTM II (Clontech-Takara) probes for OPN, IL-12B and IFN-. All reactions were
normalized using GAPDH as an endogenous control. Amplification data were
analyzed using the  Ct method.

Flow cytometry
FITC-labeled anti CD3 (HIT3a), CD14 (M5E2), CD19 (HIB19) and CD56 (B159)
antibodies were obtained from BD Biosciences (Billerica, MA, USA). Alexa Fluoro®
647-labeled anti OPN antibody (EPR3688) was obtained from Abcam. After staining
for cell surface markers (CD3, CD14, CD19 and CD56), the cell membrane was
permeabilized by 0.2 % Triton X-100 and 0.2 % digitonin, and then stained for OPN.
Flow cytometric analysis was performed with FACSCanto system and FACSDiva
software (BD Biosciences).

ELISA
ELISA kits for OPN, IL-12AB, IFN- and HE4 were obtained from R&D Systems.
The assays were performed following the manufacturer’s instructions.
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Viability and migration assays
1 x 103 / well SKOV3 cells were seeded in a 96-well culture plate. After overnight
incubation with serum free medium, conditioned media was added to the quiescent
cells that were cultured for 24, 48 and 72 hours. The cell viabilities at each time point
were evaluated using CellTiter-Blue® (Promega, Madison, WI, USA). Cell migration
assays were performed using InnoCyteTM Cell Migration Assay (EMD Millipore,
Taunton, MA, USA). 5 x 104 SKOV3 cells were seeded in the upper chamber of a 96well plate with the lower chamber containing the PBMC-conditioned media.
Migration activities were accessed after incubating the cells for 24 hours in a CO2
incubator at 37 °C.

Immunohistochemistry
SKOV3 cells were seeded at 0.5 x 104 / chamber in a 4-chamber slide. After overnight
incubation with serum free medium, conditioned media was added to the quiescent
cells and the cells were cultured for 48 hr. The cells were fixed with 2 %
formaldehyde and permealized by 0.2 % TritonX-100. The slides were then incubated
with a mouse monoclonal anti-Ki67 antibody (clone B56; PD Pharmingen, Franklin
Lakes, NJ, USA) overnight at 4°C in a humidified chamber. The slides were then
incubated with an ALP conjugated anti-mouse IgG (H+L) secondary antibody (BioRad, Hercules, CA, USA) for 30 minutes at room temperature. Bound antibody was
detected using the ALP substrate kit (Vector Laboratories, Burlingame, CA, USA) and
lightly counterstained with veronal acetate buffered 1% methyl green solution, pH 4.0
(Vector laboratories). PermountTM (Fisher Scientific, Ottawa, Ontario, Canada) was
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The

immunohistochemical studies were repeated four times on samples prepared from
different cultures. The proportion of Ki67 positive cells was calculated according to
the following formula: 100 × (the number of Ki67-positive nuclei/total number of
nuclei). Each image was analyzed at least four times to obtain an average labeling
index.

Western blotting
Cellular contents of HE4 in SKOV3 cell lines transfected with shRNA against HE4
were assessed by western blotting. Antibodies against HE4 were obtained from
Origene (TA326648). Anti-actin antibody (clone 2G2; EMD Millipore) was used for
detection of the internal loading control. The results were visualized with
SuperSignal™ West Pico chemiluminescent substrate (ThermoFisher Scientifics) and
analyzed with the UN-SCAN-IT gel software for Windows (Version 6.1; Silk
Scientific Inc.).

Confocal immunofluorescent microscopy
Formalin-fixed, paraffin-embedded tissue sections were cut to a thickness of 4 m.
For heat-induced epitope retrieval, deparaffinized sections in 0.01 M citrate buffer
were treated three times at 90 °C for 5 minutes using a microwave oven. After
blocking with 10% normal horse serum, sections were incubated with rabbit anti-OPN
antibody (FL-314; Santa Cruz Biotechnology) or mouse anti-CD3 (PS-1; Abcam)
overnight at 4 °C, washed with PBS and incubated with DyLight 488 goat anti-rabbit
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IgG (DL1488; Vector Laboratories) or DyLight 594 horse anti-mouse IgG (DL2594;
Vector Laboratories) secondary antibodies for 1 hour at room temperature in the dark.
Slides were washed again with PBS and cover-slipped with DAPI-containing
mounting medium (Vector Laboratories). Confocal images were acquired with a
Nikon C1si confocal (Nikon Inc. Mellville, NY, USA) using diode lasers 402, 488 and
561. Ten fields/sample were randomly selected based on DAPI staining and counts
were performed for CD3 and OPN using a 40x objective. Counts are expressed as # of
positive cells/mm2. All donors of the biopsies and the PBMCs provided written
informed consent. The study was approved by the Women & Infants Hospital ethics
committee.

Statistics
Data ware expressed as average ± SEM of at least three independent experiments. An
unpaired, two-tailed Student t-test was used to determine significance. Multiple
treatments were analyzed by using one-way ANOVA followed by Ryan’s multiple
comparison test. Spearman's rank correlation test was used to assess the
immunofluorescent staining on biopsy specimens. Differences between groups were
considered statistically significant when p < 0.05.

I.4 Results
Differential expression of PBMC genes after HE4 exposure
To identify differentially expressed genes after HE4 exposure, modified subtractive
hybridization was performed. PCR products of the differentially expressed genes were
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cloned into pUC19-TA vectors to create a differential cDNA library. PCR products
from 252 HE4-induced and 253-HE4 suppressed gene colonies were sequenced
resulting in the identification of 211 induced genes and 208 suppressed genes. Among
the identified genes, 23 induced and 15 suppressed sequences showed no significant
similarity (NSS) to known genes in available nucleotide databases. Among the 208
suppressed genes, OPN emerged as the most frequently identified gene (6 times out of
253 sequences, 2.4%; Table 1).

HE4 reduces OPN expression in PBMCs
HE4-induced suppression of osteopontin in PBMCs was then confirmed via three
modalities: flow cytometry, quantitative PCR (qPCR), and ELISA using PBMCs from
four individual donors. First, PBMCs were cultured with recombinant human HE4
(rHE4; 0.01 g / mL) for 24 hours and collected for flow cytometry analysis. Protein
expression of OPN in CD3+ PBMCs (T cells) was found to be significantly reduced
with HE4 exposure (48.8 ± 1.0 % vs 37.4 ± 1.0 %; p < 0.05; Figure 1A). PBMCs were
harvested after a 6-hour incubation with rHE4 (0.01 g / mL), revealing a 0.70 ± 0.03fold reduction in OPN mRNA production (Fig 1B). PBMCs were then exposed to
rHE4 (0.01 g / mL) for 24 hours and concentrations of OPN in the cell lysates and
the culture supernatants were measured by ELISA. The concentrations of OPN in
lysates (159.82 ± 3.14 vs 103.61 ± 3.23 pg / mL, p < 0.01) and culture supernatants
(53.37 ± 3.14 vs 30.08 ± 3.48 pg / mL, p < 0.01) were also decreased with HE4
exposure (Figure 1C).
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HE4-mediated IL-12 and IFN- reduction in PBMCs is reversible with
supplementation of OPN
In lipopolysaccharide-stimulated macrophages, OPN has been shown to enhance IL12 production and suppress IL-10 production, thereby promoting Th1 activity (17, 18).
In order to estimate the impact of HE4 on PBMCs, transcriptional expression and
protein levels of Th1 related cytokines IFN- and IL-12 were evaluated. Cells were
incubated with either: (a) vehicle control, (b) 0.01 g / mL rHE4 or (c) 0.01 g / mL
of rHE4 and 20 pg / mL rOPN for 6 hours and cell lysates and/or culture supernatants
were taken for qPCR and ELISA. As shown in Figure 2A, relative expressions of IL12B and IFN- mRNA were decreased (61% and 69% respectively) upon treatment
with rHE4. This suppression was partially reversed by the addition of recombinant
OPN (rOPN) to culture conditions. Protein expression, as determined by ELISA, is
shown in Figure 2B. IL-12 concentrations, both in lysates and culture supernatants,
were reduced after HE4 exposure (4.81 ± 0.17 to 2.05 ± 0.08 pg / mL in cell lysate and
7.17 ± 0.26 to 3.56 ± 0.20 pg / mL in supernatant). The addition of rOPN resulted in a
nearly complete reversal of HE4-mediated IL-12 suppression. Similarly, IFN concentrations in the cell lysates and supernatant decreased significantly with rHE4
treatment (from 35.55 ± 1.03 to 14.41 ± 1.10 pg / mL and from 19.92 ± 0.82 to 11.10
± 0.59 pg / mL, respectively) and the addition of rOPN again caused recovery of the
cytokine levels.

Conditioned media from HE4-treated PBMCs enhanced the viability, proliferation,
and invasiveness of ovarian cancer cells
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In order to assess the effects of PBMC-produced soluble factors on cancer cell
activity, SKOV3, an immortalized ovarian cancer cell line, was incubated with the
conditioned media from PBMC cultures (2 x 106 / mL density) with or without rHE4.
SKOV3 cells cultured with HE4-treated PBMC media showed significantly higher
viability than cells cultured with the HE4-depleted PBMC conditioned media at 48
hours (1773.84 ± 436.38 vs. 3081.17 ± 348.03, p < 0.01) and 72 hours (3146.67 ±
494.87 vs. 4568.84 ± 407.74, p < 0.01; Figure 3A). Next, a cell migration assay was
employed to determine whether conditioned media from rHE4-exposed PBMCs
affects ovarian cancer migration as a surrogate of metastatic capability. The SKOV3
cells that were incubated with HE4-exposed PBMC media showed more extensive
migration than control cells (RFU of 1147.21 ± 365.09 vs. 3138.14 ± 419.66, p < 0.01,
Figure 3B). Immunohistochemistry using anti-Ki67 was performed to evaluate the
proliferation of SKOV3 cells in the presence of rHE4-exposed PBMC media or
vehicle-exposed conditioned media. The proliferation rate of tumor cells in HE4exposed PBMC conditioned media was higher than control media (63.8 ± 18.1 vs 39.9
± 7.6 %, p < 0.01, Figure 3C). These findings suggest that PBMCs alter their soluble
factor release under the influence of rHE4, thus enhancing the viability, proliferation
and migration capabilities of the cultured ovarian cancer cells.

HE4 inhibition increases ovarian cancer susceptibility to PBMC-mediated cytotoxicity
In order to evaluate the impact of native (tumor-cell produced) HE4 on PBMCs,
SKOV3 cells were co-cultured with PBMCs after stable transfection with HE4
specific shRNA (shHE4) or a scrambled oligonucleotide control plasmid (SO). Clones
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of shRNA transfected cells were tested for their phenotype by western blotting and
ELISA (Figure S5). After a 2-hour incubation at 37 °C, the effector cells were washed
away and the target cells were analyzed by flow cytometry. The silencing of HE4 in
SKOV3/PBMC co-cultures led to a significant increase in IL-12 and IFN
concentrations (Table 2). As shown in Figure 4, HE4 silencing also increased tumor
cell susceptibility to PBMC cytotoxicity, an effect that was reversed by the addition of
rHE4. Furthermore, this “rescue” by rHE4 was at least partially abrogated by the
addition of recombinant IL12 (rIL-12) or recombinant IFN- (rIFN-) to the culture
conditions. These findings suggest that the native HE4 production by ovarian cancer
cells is critical to cell-mediated cytotoxicity resistance.

Ovarian cancer patient prognosis correlates to the number of intra- and peri-tumoral
CD3+ T cells and stromal OPN-producing cells
Twenty biopsies from high-grade serous ovarian cancer patients were evaluated by
dual fluorescent stain with antibodies against CD3 and OPN (Table 3). In the tumor
segments of the biopsy specimen, some CD3- tumor cells showed high OPN
expression, while in the stromal area of the biopsy the principal OPN+ cells were
CD3+ T cells (Figure 5A). A significant portion of the stromal CD3+OPN+ cells was
accompanied by strong OPN staining in their cytosols or the surrounding areas (Figure
5B). In order to investigate the clinical relationship of HE4, OPN and CD3, numbers
of T cells (CD3+) and total OPN+ cells were correlated with pre-operative serum HE4
level (available for 13 patients) or PFS duration (available for 16 patients). The
numbers of CD3+ infiltrating T cells, both in the tumor and stroma, were directly
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proportional (tumor, r = 0.541, p = 0.03; stroma, r = 0.512, p = 0.02) to the patients’
PFS duration (Figure 5C). Additionally, the number of OPN+ cells, both in tumor and
stroma, were in inversely proportional (tumor; r = -0.635, p = 0.019, stroma; r = 0.582, p = 0.037) to serum levels of HE4. Moreover, the number of OPN+ cells in the
stroma (but not in the tumor) were directly proportional to the patients’ PFS duration
(r = 0.711, p = 0.002; Figure 5D). These findings suggest that tissue infiltrating T cells
play a critical role in the suppression of ovarian cancer progression.

I.5 Discussion
HE4 is known to be highly overexpressed in ovarian cancer, but its causal relationship
to ovarian tumorigenesis has not been firmly established. Emerging studies suggest
that HE4 overexpression promotes ovarian tumor growth and imparts strong resistance
against the most commonly used chemotherapeutics (20-24). Accordingly, serum HE4
level is an early predictor of platinum resistance (9, 23), and ovarian cancer patients
that experienced greater HE4 reduction during neoadjuvant chemotherapy exhibited
improved overall survival (24). Our study has shown a novel role for HE4 in the
inhibition of immune cell activity through OPN suppression. We identified the gene
for OPN, SPP1, as the most prominently suppressed gene in PBMCs in response to
HE4 exposure in vitro. Additionally, HE4 was found to downregulate OPN production
in CD3+ T cells. It is important to note that the changes in OPN expression in T cells
after HE4 exposure are quite modest according to the flow cytometric analysis, and
this raises the question of whether these small differences translate into functional
consequences. However, the changes in OPN levels determined by qPCR and ELISA
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(Figure 1B and C) appear much more robust. These findings suggest that the secretion
of OPN is an important factor to include in the assessment of the biological response
to HE4. In accordance with this hypothesis, we confirmed suppressed secretion of
OPN-induced cytokines IL-12 and IFN- in the rHE4 exposed PBMCs HE4’s
inhibition of immune cell function was further clarified by our co-culture experiments
showing reduced antitumoral cytotoxicity.
OPN is primarily considered a pro-tumorigenic protein. In various types of cancers,
serum OPN levels are directly proportional to degree of malignancy and inversely
proportional to patient survival (25-27). OPN also plays a critical role in tumor
formation and growth by promoting cancer cell survival, proliferation, metastasis, and
angiogenesis (28, 29). On the other hand, some studies describe anti-tumor effects of
OPN (30-33). Among them, Crawford et al., with elegantly designed cancer cell
inoculation experiments using OPN null mice, demonstrated that host-derived OPN
acted as a chemoattractant to enhance the host defense activity of macrophages,
whereas tumor-derived OPN inhibited macrophage function to enhance the growth or
survival of cancers (30). In our study, the number of OPN+ cells in stroma (mainly
CD3+ T cells), but not in tumor (mainly CD3- tumor cells), correlated positively to
patients’ PFS durations. The dichotomic function of OPN presented by Crawford et al.
may serve as an explanation of the findings in the present study.
In summary, this study is the first to implicate HE4 in ovarian cancer immune escape
and provide the rationale for targeting HE4 to restore normal tumor immune editing.
We are currently working to identify small molecules and/or neutralizing antibodies to
further validate the utility of HE4 inhibition as a novel immunotherapeutic in the
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treatment of ovarian cancer. However, several barriers remain in the achievement of
this objective. For example, PBMCs in ovarian cancer patients may already be
exposed to a chronically high level of HE4, which may have differing effects than the
acute exposure performed in our study. Secondly, due to multiple complicated steps in
the subtractive hybridization procedure, this study stands on the data from a single
donor. The benefit of this experimental strategy lies in perspicuous outcomes;
however, it also introduces inherent limitations in interpretation of the results. To
begin to circumvent this pitfall, we validated the HE4-mediated downregulation of
OPN using flow cytometry, qPCR, and ELISA in PBMCs from four healthy donors.
This issue will be further addressed in subsequent studies on HE4. Lastly, it is
important to note that OPN is known to play a role in humoral immunity (34-36).
Further studies are required to fully understand the role of HE4 and OPN in humoral
immunity in relation to ovarian cancer. Additionally, as we showed in Table 1 that
PBMCs modulated a variety of genes in response to HE4 exposure. It is therefore very
likely that other factors, besides osteopontin, are also contributing to in the inhibitory
effect of HE4 on the immune system. Further analysis of the functions of these genes,
and how they are associated with HE4, is warranted.
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Figure I.1 HE4 downregulates expression of OPN in PBMCs.
(A) Two-color flow cytometric analysis of PBMC following a 24-hour incubation
with 0.01 g / mL of rHE4 (HE4) or vehicle (CTR). 2D-scatterplots of OPN (Alexa
Fluor 647) and CD3 (FITC) are shown. The numbers on the scatterplots represent
mean ± SEM % of each quadrant. (B) OPN transcription in response to a 6-hour
incubation with 0.01 g / mL rHE4 (HE4) or vehicle (CTR) were evaluated by real
time PCR. A bar graph represents relative expression levels against control. (C) OPN
concentrations of PBMC lysates and culture supernatants after a 24-hour incubation
with 0.01 g / mL of rHE4 (HE4) or vehicle (CTR) were evaluated by ELISA. All the
experiments were done with PBMCs from four individual donors and repeated 3 (A),
9 (B) and 10 (C) times. The mean is shown in the bar graphs; error bars represent
SEM (n > 10). * p < 0.05, **p < 0.01.
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Figure I.1
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Figure I.2 HE4 suppresses expression and secretion of IL-12 and IFN- by PBMCs.
(A) PBMCs were incubated for 6 hours in serum free media under the indicated
conditions (vehicle, 0.01 g / mL rHE4 and rHE4 + 20 pg / mL of rOPN). After a
6- hour incubation, transcription levels of IL-12B (p40) and IFN- were evaluated by
real time PCR. A bar graph represents relative expression levels against control. (B)
The concentrations of IL-12AB (p70) and IFN- in the cell lysates and the culture
supernatants from 24-h incubation under the same conditions were measured by
ELISA. All the qPCRs and ELISAs were done with PBMCs from four individual
donors. Each assay was repeated 4 times (qPCR) or 10 times (ELISA). The mean is
shown; error bars represent SEM. * p < 0.01.
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Figure I.2

A

B
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Figure I.3 Responses of SKOV3 and OVCAR8 human ovarian cancer cell lines to
PBMC conditioned media.
(A) Cells were incubated with conditioned media from the PBMC culture treated with
vehicle (blue line) or rHE4 (red line). The cell viabilities were assessed at 24, 48 and
72 hours after treatment (n = 10 for 0 hours, n = 8 for 24, 48 and 72 hours). (B) Cell
migration activities with conditioned media were assessed at 24 hours of incubation (n
= 10). (C) Ki67 immunohistochemistry staining was performed on SKOV3 /
OVCAR8 cell lines incubated with the PBMC conditioned media for 24 hrs. Ki67+
cells are identified with red nuclear staining (upper panel). Bar graph (lower panel)
represents the percentage of Ki67+ cells in total countable cells under 200x fields (n =
6). Scale bar: 50 m. The mean is shown; error bars represent SEM (n = 10). * p <
0.05, ** p < 0.01.
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Figure I.3

85

Figure I.4 Flow cytometric analysis of the cytotoxicity of mononuclear cells against
SKOV3 tumor cells.
Cell membranes of SKOV3 (target) cells were labeled with DiOC18(3) fluorescent dye
and then incubated with PBMCs in the presence of propidium iodide (PI) as a marker
of cell death. After washing away the non-adherent cells (PBMCs), the PI positive
tumor cells were quantitated via flow cytometry (upper panel). The numbers on the
histograms represent mean percentage of each bisection. The bar graph (lower panel)
represents percentages of PI positive (dead / dying) cells in various culture conditions.
The mean is shown; error bars represent SEM (n > 10). * p < 0.01, **p < 0.05.
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Figure I.4
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Figure I.5 Confocal immunofluorescent analysis of CD3 and OPN expression in
biopsy samples.
Twenty biopsies (listed in Table 3) were evaluated. (A) Stromal and tumoral CD3+
cells and OPN+ tumor cells are indicated by arrowhead. A biopsy from a benign
serous tumor (Benign) and an uninvolved section of oophorectomy (Normal) were
utilized as a negative control (B). Enlarged image depicting image co-staining of
stromal and tumoral CD3+/OPN+ T cells in their cytosol or the surrounding area (C,
D). Graphic representations of Spearman's rank correlations between the numbers of
CD3+ or OPN+ cells and clinical parameters. CR; corrected ranks.
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Figure I.5
Figure I.5 a & b

A

B
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Figure I.5 c & d
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Table I. 1 Genes suppressed in response to HE4

Table 1
Genes suppressed in response to HE4
Frequency ID
gene name
15
6
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

1

NSS
NM_001040058
NM_015574
NM_001693
NM_000206
NM_022818
NM_001243121
NM_080792
NM_015131
NM_001025604
NM_001164755
NM_032408
NM_002985
AC132216
NC_018926
NM_001291549
NM_014280
XM_011535514
XM_011518416
NM_020447
NG_029887
NM_002107
NM_001128619
NM_002463
NM_004687
NM_001251855
NM_000437
NR_049751
NM_001198719
NM_001028
XM_011534644
NM_001242933
XR_241300
NM_181892
NM_006007

no significant similarity
secreted phosphoprotein 1 (SPP1), transcript variant 1
ankyrin repeat domain 17 (ANKRD17)
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 (ATP6V1B2)
interleukin 2 receptor subunit gamma (IL2RG)
microtubule-associated protein 1 light chain 3 beta (MAP1LC3B)
phosphodiesterase 4A (PDE4A)
signal regulatory protein alpha (SIRPA)
WD repeat domain 43 (WDR43)
arrestin domain containing 2 (ARRDC2)
aspartate beta-hydroxylase (ASPH)
bromodomain adjacent to zinc finger domain, 1B (BAZ1B)
chemokine (C-C motif) ligand 5
chromosome 11, clone RP13-786C16
chromosome 15, alternate assembly CHM1_1.1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)
DnaJ (Hsp40) homolog, subfamily C, member 8 (DNAJC8)
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)
family with sequence similarity 120A (FAM120A)
family with sequence similarity 219 member B (FAM219B)
golgin A3 (GOLGA3)
H3 histone, family 3A (H3F3A)
leucine zipper protein 6 (LUZP6)
MX dynamin-like GTPase 2 (MX2)
myotubularin related protein 4 (MTMR4)
phosphoinositide-3-kinase regulatory subunit 5 (PIK3R5)
platelet-activating factor acetylhydrolase 2, 40kDa (PAFAH2),
reticulon 3 (RTN3)
retinoblastoma binding protein 7 (RBBP7)
ribosomal protein S25 (RPS25)
serine/threonine kinase 10 (STK10)
sorting nexin 1 (SNX1)
splicing factor 3b, subunit 1, 155kDa (SF3B1)
ubiquitin-conjugating enzyme E2D 3 (UBE2D3)
zinc finger, AN1-type domain 5 (ZFAND5)

159 genes
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Table I. 2 Concentrations of IL-12, IFN-γ and HE4 in co-culture medium

Concentrations of IL-12, IFN- and HE4 in co-culture
medium
INF- (ng/mL)
Target Effector
IL-12 (ng/mL)
SC
14.84±0.48
SC
+
177.20±1.07
shHE4
shHE4
+
31.95±0.68**
417.74±3.54**
SC; SKOV3 with scrambled oligo, shHE4; SKOV3 with
HE4 shRNA
mean ± SE is shown (n = 10)
*p<0.01 vs. SC, **p<0.01 vs.SC + Effector cells
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HE4 (pM)
534.15±41.81
639.01±50.38
174.12±18.55*
237.91±34.24**

Table I.3 Clinical Parameters of Donors

Table 3
Clinical parameters of donors of biopsies
pre-OP sHE4*
PFS**
Sample ID
(pmol/mL)
(months)
S10-10110
174
10
S10-10726
na
16
S10-15910
na
25
S10-17790
376
12
S10-18470
529
22
S10-4387
462
31
S10-5618
na
9
S10-5842
na
na
S10-6697
150
na
S10-7183
1232
na
S11-1189
3289
8
S11-2223
550
28
S11-2493
591
37
S11-2684
3255
24
S11-3415
na
na
S11-622
na
38
S11-6675
4702
16
S11-6721
na
64
S11-7794
410
38
S11-8032
623
21
* pre-operation serum HE4
** progression-free survival
na; not available
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II.1 Abstract

Objective
Selective overexpression of Human epididymal secretory protein 4 (HE4) points to a
role in ovarian cancer tumorigenesis but little is known about the role the HE4 gene or
the gene product plays. Here we examine the role of the secretory glycoprotein HE4 in
ovarian cancer immune evasion.
Methods
Through the modified subtractive hybridization analyses of human peripheral blood
mononuclear cells (PBMCs), we have characterized gene targets of HE4 and
established a preliminary mechanism of HE4-mediated immune failure in ovarian
tumors.
Results
Dual specificity phosphatase 6 (DUSP6) emerged as the most upregulated gene in
PBMCs upon in vitro exposure to HE4. CD8+ cells and CD56+ cells found to be
sources of the upregulated DUSP6. The HE4 exposure enhanced Erk1/2
phosphorylation specifically in these cell populations and the effect was erased by coincubation

with

DUSP6

inhibitor,

(E)-2-benzylidene-3-(cyclohexylamino)-2,3-

dihydro-1H-inden-1-one (BCI). In co-culture with PBMC, HE4-silenced SKOV3, a
human ovarian carcinoma cell line, exhibited enhanced proliferation with exposure to
the external HE4; this effect was partially attenuated by adding BCI to the culture.
Additionally, the reversal effects of BCI were erased in the co-culture with CD8+ /
CD56+ cell deprived PBMC.
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Conclusion
Taken together, these findings show that DUSP6 is a suppressor of the cytotoxicity of
the CD8+ and CD56+ lymphocytes and HE4 enhances tumorigenesis of ovarian cancer
through the compromised cytotoxicity of the CD8+ and CD56+ cells by upregulation
of self-produced DUSP6, which acts as an autocrine factor.
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II.2 Introduction
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women,
and the deadliest gynecologic cancer. The American Cancer Society estimates that in
2017, there will be an estimated 22,440 new cases of EOC and 14,080 deaths in the
United States [1]. Only 15% of patients are diagnosed at an early stage when the
disease is fundamentally curable, keeping the 5-year survival rate at a dismal 46% [2].
Recurrence following initial treatment is common, occurring in approximately 80% of
cases, and all patients with recurrent disease eventually succumb to their illness [3].
These dire statistics highlight the need for continued research into improved diagnostic
and treatment options for EOC.
Despite continued efforts, there remains a lack of effective treatments for EOC.
Standard first-line therapy consists of debulking surgery followed by taxane-platinum
chemotherapy[3]. Other targeted therapies are also employed, including the
antiangiogenic drug bevacizumab and the PARP inhibitor olaparib; however, these
treatments have not led to an improvement in overall survival [4]. One promising new
area of investigation lies in understanding how tumors develop immune tolerance and
evade elimination by cytotoxic lymphocytes. Immune checkpoint molecules such as
PD-1, CTLA4, TIM3, IDO, and others, suppress T cell activation and help tumor cells
escape targeting and elimination by the immune system [5]. Nivolumab, a monoclonal
antibody against PD-1, is expressed on T cells and suppresses their activation upon
binding of its tumor cell associated ligands, PDL1/PDL2, has greatly improved
survival for metastatic melanoma patients [6]. PD-1 has also been studied in relapsed
platinum-resistant EOC; however, overall response rates for EOC do not exceed 15%
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[7]. This inefficacy of immune checkpoint inhibitors is likely due to compensatory
immune suppressive pathways [8,9], or activation of oncogenic pathways that promote
immune tolerance [5]. Overall, we require a greater understanding of factors that
contribute to immune evasion in EOC in order to develop treatments that reactivate the
body’s immune response to tumors.
Human epididymis protein-4 (HE4) is a member of the whey acidic four-disulfide core
protein family [10]. It is elevated in tumor tissue and serum of EOC patients, and is
used as part of the Risk of Ovarian Malignancy Algorithm (ROMA)—along with
CA125 and menopausal status—for the diagnosis and management of EOC [11, 12].
ROMA shows greater sensitivity and specificity for the detection and monitoring of
EOC than the Risk of Malignancy Index, which uses CA125, pelvic sonography, and
menopausal status [12]. HE4 also has the advantage of presenting fewer false positives
than CA125 in the case of benign gynecologic disorders [11, 13]. In vitro and in vivo
studies have shown that HE4 promotes multiple aspects of ovarian cancer aggression,
including

growth

and

proliferation;

invasion,

migration,

and

adhesion;

chemoresistance, and anti-estrogen resistance [14–23]. Clinically, patients with high
levels of serum HE4 have greater chemoresistance and worse prognosis [22, 24–26].
We hypothesized that HE4 may also promote immune evasion in EOC. We began to
test this hypothesis by determining HE4-mediated gene expression in peripheral blood
mononuclear cells (PBMCs), and went on to evaluate the effect of HE4 and one of its
targets, DUSP6, on immune cell function and cytotoxicity against ovarian cancer cells.
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II.3 Methods
Subtractive hybridization and TA-cloning
5 x 107 PBMCs from single donor were suspended in 5 mL of serum free RPMI1640
medium (Invitrogen, 31800) and incubated with or without 0.01 g/mL of rHE4
(Abcam, ab184603) for 6 hours. Then, total RNA was isolated using TRIzolTM
Reagent (Invitrogen, 15596018). Next, mRNA was purified using MagnosphereTM
UltraPure mRNA Purification Kit (Takara-Clontech, 9186). From the 5 g of mRNA,
subtractive cDNA libraries were constructed using PCR-SelectTM cDNA Subtraction
Kit (Takara-Clontech, 637401) following the manufacturer’s protocols. PCR products
of the differentially expressed genes were cloned into a pUC19-TA vector. Top 10
competent cells (Invitrogen, C404003) were transformed with the clones and were
seeded on a Xgal/IPTG containing LB/ampicillin plates. The colonies of clones
containing the inserts were selected by blue/white selection and were amplified by
direct colony PCR using LA Taq® DNA polymerase (Takara-Clontech, RR002A) and
M13 primers.

Cell culture
Primary human PBMCs were obtained under the auspices of Women & Infants
Hospital IRB approval from total blood of four individual volunteer by density
gradient centrifugation using Histopaque®-1077 (Sigma-Aldrich, 10771). The human
ovarian tumor cell line, SKOV3, human NK cell line, NK-92MI, human T cell line,
TALL-104 and H9 were obtained from ATCC (HTB-77, CRL-2408, CRL-11386 and
HTB-176, respectively). RPMI1640 was used for culturing PBMC and lymphocyte
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lines and DMEM (Invitrogen, 31600) were used for SKOV3. Conditioned media were
obtained from a 24-hour PBMC culture. Residual rHE4 in the conditioned media was
deprived as follows. Five mL of media was incubated with 10 g (100 L) of antihuman HE4 antibody (Santa Cruz Biotechnology, sc-293473) for 1 hour at 4 degrees.
And then, 100 mL packed volume of protein G coated sepharose beads (GE
Healthcare Life Science, 17061801) were added to the media and incubated for 4
hours at 4 degrees. After the incubation, the sepharose beads were removed by
centrifugation and the supernatants were processed through sterile 0.2 m pore syringe
filter. For the cell-mediated cytotoxicity assay, 1 x 106 target cells (SKOV3) were
seeded on 6-well plates, and then were incubated overnight with complete media. The
next day, cells were placed in serum free media for another overnight incubation and
then 5 x 106 / mL of the effector cells (PBMCs) were added to the quiescent target
cells. After a 12-hour incubation, the effector cells were washed away and harvested
target cells were stained with 1 g / mL of propidium iodide with or without Alexa
Fluor® 488 labeled annexin V (Invirogen, V13241). Some of the wells contained 0.01
g/mL

of

rHE4

and

1

M

of

DUSP6

inhibitor,

(E)-2-benzylidene-3-

(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI; Sigma-Aldrich, B4313). All
experiments were performed under serum free condition.

Flow cytometry
FITC-labeled anti CD3, CD4, CD8, CD14, CD19 and CD56 antibodies were obtained
from BD Biosciences (555916, 561005, 560960, 555397, 555412 and 562794,
respectively). Alexa Fluor® 647-conjugated anti DUSP6 antibody was obtained from
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Abcam (ab200751). Alexa Fluor® 647-conjugated anti phosphor-p44/42 MAPK
antibody was obtained from Cell Signaling Technology (13148). After staining for cell
surface markers (CD3, CD14, CD19 and CD56) the cell membrane was permeabilized
by 0.2 % Triton X-100 and 0.2 % digitonin, and then stained for DUSP6 or phosphorp44/42-MAPK. Flow cytometric analysis was performed with FACSCanto system and
FACSDiva software (BD Biosciences).

Quantitative Real-Time PCR
RNA was isolated from cells using TRIzol (Invitrogen, A33250) according to the
manufacturer’s instructions. cDNA was synthesized using SuperScript III reverse
transcriptase (Invitrogen, 18080093). qPCR was performed using Premix Ex-TaqTM II
(Clontech-Takara, 639676) probes for DUSP6. All reactions were normalized using
GAPDH as an endogenous control. Amplification data were analyzed using the Ct
method.

ELISA
ELISA kits for HE4 and DUSP6 were obtained from MyBioSource (MBS280223 and
MBS073193, respectively). The assays were performed following the manufacturer’s
instruction.

Western blotting
Phosphorylation of Erk1/2 in NK-92MI, TALL-104 and H9 cell lines were assessed
by western blotting. Antibodies against phosphorylated and total Erk1/2 MAPK were
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obtained from Cell Signaling Technology (9101 and 4695). The results were
visualized with SuperSignal™ West Pico chemiluminescent substrate (ThermoFisher
Scientifics, 34080) and analyzed with the UN-SCAN-IT gel software for Windows
(Silk Scientific Inc.).

HE4 silencing with shRNA
shRNA for human HE4 (Origene, TR318721) were transfected into SKOV3 using
Lipofectamine® 2000 (Invitrogen, 11668) following the manufacture’s instruction.
Individual single cells were selected by culturing under the pressure of 5 g / mL of
puromycin (Research Products International, 58-58-2).

Cell viability assay
1 x 103 / well SKOV3 cells were seeded in a 96-well culture plate. After overnight
incubation with serum free medium, 5 x 106 /mL of effector cells (PBMCs) were
added to the quiescent cells. The cell viabilities were evaluated at 24, 48 and 72 hours
using fluorescent based CEllTiter-Blue® (Promega, G8080) and Spectra Max Gemini
EM fluorescent micro plate reader (Molecular Devices).

Immunohistochemistry
0.5 x 104 / chamber of SKOV3 cells were seeded in a 4-chamber slide. After overnight
incubation with serum free medium, 5 x 106 /mL of effector cells (PBMCs) were
added to the quiescent cells and the cells were cultured for 48 hrs. Ki67 positive cells
were counted in twenty of 200x fields. A mouse anti-Ki67 monoclonal antibody was
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purchased from BD Biosciences (550609). An alkaline phosphatase (ALP) labeled
anti-mouse IgG secondary antibody and an ALP substrate kit were obtained from
Vector laboratories (AP-2000, SK-5100).

Depletion of CD8+ and CD56+ cells from PBMCs
CD8+ and CD56+ cells were removed from PBMC using magnetic CD8 and CD56
MicroBeads (Miltenyi Biotec, 130-045-201 and 130-050-401) with autoMACS cell
separator (Miltenyi Biotec, 130-092-545). Briefly, 5 x 107 of PBMC was suspended in
60 L of separation buffer (PBS, pH 7.2 with 0.5 % BSA and 2 mM EDTA), and then,
20 L each of CD8 and CD56 MicroBeads were added to it, followed by 15 minutes
incubation at 4 degrees. After washing, resuspended the cells in 500 L of the
separation buffer and proceed to magnetic separation using autoMACS® Columns
(Miltenyi Biotec, 130-021-101). Unlabeled cells that pass through were collected and
combined with total effluent from washed column.

Statistics
Data ware expressed as average ± SEM of at least four independent experiments. An
unpaired, two-tailed Student t-test was used to determine significance. Multiple
treatments were analyzed by using one-way ANOVA followed by Ryan’s multiple
comparison test. Differences between groups were considered statistically significant
when p < 0.05.
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III.4 Results
Differential expression of PBMC genes after HE4 exposure
To identify differentially expressed genes after HE4 exposure, modified subtractive
hybridization was performed. PCR products of the differentially expressed genes were
cloned into pUC19-TA vectors to create a differential cDNA library. PCR products
from 250 each of HE4-induced and HE4-suppressed gene colonies were sequenced
resulting in the identification of 209 induced genes and 206 suppressed genes. Among
the identified genes, 20 induced and 13 suppressed sequences showed no significant
similarity (NSS) to known genes in available nucleotide databases. Among the 209
induced genes, dual specificity phosphatase 6 (DUSP6) emerged as one of the most
frequently identified genes (3 times out of 250 sequences, 1.2%; Table 1).

HE4 induces DUSP6 expression in PBMCs
HE4-induced upregulation of DUSP6 in PBMCs was then confirmed via three
modalities: quantitative PCR (qPCR), ELISA and flow cytometry. First, PBMCs were
harvested after a 6-hour exposure with recombinant human HE4 (rHE4; 0.01g/mL),
revealing a 1.60 ± 0.13-fold increase (p < 0.01) in DUSP6 mRNA production (Figure
1A). The concentrations of DUSP6 in PBMC lysates (9.38 ± 0.62 vs 15.62 ± 0.97
ng/mL, p < 0.01) and culture supernatants (0.77 ± 0.10 vs 1.43 ± 0.14 ng / mL, p <
0.01) after a 24-hour exposure to rHE4 were also increased (Table 2). PBMCs were
then cultured with rHE4 for 24 hours and collected for flow cytometry analysis.
Protein expression of DUSP6 in CD3+ PBMCs (T cells) was found to be significantly
increased with HE4 exposure (34.4 ± 0.6 % vs 47.0 ± 3.2 % of total CD3+ cells; p <
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0.05; Figure 1B left panel). The DUSP6 expression in CD56+ cells (NK/T cells, NK
cells) was also increased to a lesser extent (34.1 ± 2.3 % vs 41.7 ± 1.7 % of total
CD56+ cells; p < 0.05; Figure 1B right panel). In order to identify a T cell subset
involved in the HE4 responsive induction of DUSP6, two-color flow cytometry using
anti-DUSP6 antibody and anti-CD4 (helper T cell) or CD8 (cytotoxic T cell)
antibodies were performed. As shown in Figure 2, after a 24-hour exposure to rHE4,
CD8+ T cells (9.9 ± 0.8 % vs 1.9 ± 0.1 %; p < 0.01) but not CD4+ T cells (15.6 ± 1.4
% vs 15.4 ± 1.5 %) showed significant DUSP6 induction. These finding suggested that
the CD8+ and CD56+ cytotoxic mononuclear cells were responsible for the HE4
responsive DUSP6 induction.

CD8+ and CD56+ cytotoxic lymphocytes are targets of HE4 induced DUSP6
In order to identify effector cells for the HE4 induced DUSP6, two-color flow
cytometry using antibodies against phosphor-Erk1/2 (pErk1/2) and CD4, CD8, CD14,
CD19 and CD56 were performed. Significant decreases of pErk1/2+ populations were
observed in CD8+ (30.2 ± 2.4 % vs 4.3 ± 0.2 % in total CD8+ cells; p < 0.01) and
CD56+ (32.3 ± 4.0 % vs 5.4 ± 0.6 % in total CD56+ cells; p < 0.01) cells after a 24
hours rHE4 (0.01 g/mL) exposure, and the decreases were abrogated by co-treatment
with 1 M of DUSP6 inhibitor, (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro1H-inden-1-one (BCI) in both CD8+ cells and CD56+ cells (23.3 ± 0.7 % and 30.5 ±
2.6 %, respectively; Figure 3A). Next, CD56+ NK cell line (NK92MI), CD8+ cytotoxic
T cell line (TALL-104) and CD4+ helper T cell line (H9) were incubated with the
conditioned media from a 24- hour PBMC culture with or without rHE4 and BCI for 1
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hour. The lysates of the cells were used for western blotting to evaluate Erk1/2
phosphorylation. As shown in Figure 3B, 1-hour incubation with the HE4 exposed
PBMC conditioned media suppressed Erk1/2 phosphorylation in NK92MI cell (0.67 ±
0.07-fold vs CTR, p < 0.01) and TALL-104 cell (0.56 ± 0.10-fold vs CTR, p < 0.01)
but not in H9 cell (1.01 ± 0.03-fold vs CTR). The rHE4 responsive pErk1/2
suppressions were abrogated by the PBMC conditioned media from co treatment with
rHE4 and BCI in both NK92MI (0.90 ± 0.04-fold vs CTR) and TALL-104 (0.89 ±
0.06-fold vs CTR). These findings suggested that the HE4 induced DUSP6 acts as an
autocrine suppressor for Erk1/2 MAPK in CD8+ and CD56+ cytotoxic lymphocytes.

HE4 attenuates ovarian cancer susceptibility to PBMC mediated cytotoxicity
In order to evaluate the impact of HE4 on PBMC cytotoxicity against cancer cells, the
human ovarian tumor cell line, SKOV3, was co-cultured with PBMCs (5 x 106 / mL
density). To minimize the effect of native HE4 produced by tumor cell, the SKOV3
cells were stably transfected with HE4 specific shRNA (shHE4). The effector cells
(PBMCs) were washed away, and the target cells (SKOV3) were analyzed by three
independent modalities: cell viability, Ki67 immunostaining, and flow cytometry for
propidium iodide (PI) and annexin V. First, SKOV3 cells co-cultured with PBMC
suspensions containing 0.01 g/mL of rHE4 showed significantly higher viability than
cells cultured with the rHE4 free suspensions at 24 (1222.70 ± 29.48 vs. 1517.98 ±
34.32, p < 0.01), 48 (2038.38 ± 55.94 vs. 3508.64 ± 164.98, p < 0.01) and 72 hours
(1983.33 ± 100.41 vs. 2935.89 ± 116.47, p < 0. 01), and the increased viabilities were
partially abrogated by adding 1 M of BCI to the culture (1295.68 ± 39.87, 2667.27 ±
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95.13 and 2424.50 ± 105.70, at 24, 48 and 72 hours, respectively; Figure 4A). Second,
immunohistochemistry using anti-Ki67 was performed to evaluate the proliferation
activities of SKOV3 cells in the presence of PBMCs with or without rHE4 and BCI
for 24 hours. The number of Ki67 positive tumor cells in rHE4-containing PBMC
suspension was higher than the cells in rHE4-free suspension, and the increased
activity was partially attenuated by adding BCI to the culture (27.6 ± 1.7 %, 68.5 ± 2.6
% and 48.9 ± 2.3 %, respectively; Figure 4B). Finally, after a 6 -hour incubation at 37
degrees, the effector cells were washed away and the target cells were analyzed by 2color flow cytometry using PI and Alexa Fluor® 488 labeled annexin V. As shown in
Figure 4C, SKOV3 / PBMC co-cultures with rHE4 led to a significant decrease in
populations of PI / annexin v double positive dying cells (24.3 ± 1.2 % vs. 13.4 ± 0.8
%, p < 0.01), and the tolerance of the target cells was partially reversed by adding BCI
to the culture (18.1 ± 0.6 %, p < 0.01 vs. CTR and HE4). These findings suggest that
HE4 enhances tolerance of cancer cells against immunocompetent mononuclear cells
via up-regulation of DUSP6 in PBMCs. In order to confirm involvement of CD8+ /
CD56+ cytotoxic lymphocytes in the HE4 induced immunomodulation, the co-culture
study was repeated using PBMCs deprived of CD8+ / CD56+ cells. As shown in Figure
5A-C, all the effects of BCI shown in Figure 4 were erased in the CD8+ / CD56+ cell
free co-cultures, suggesting that the cytotoxic lymphocytes play a pivotal role in the
immunoediting by DUSP6 up-regulation in response to exposure to HE4.
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II.5 Discussion
Several studies from our laboratory and elsewhere have revealed multidimensional
roles for HE4 in the pathogenesis of ovarian cancer, including the promotion of tumor
growth, chemoresistance, anti-estrogen resistance, invasion, migration, and adhesion
[14–23]. In this present study, we have begun to delineate another vital function of
HE4 in disrupting immune cell function, which has implications for immune system
targeting of tumor cells. DUSP6, which we found to be upregulated by rHE4 treatment
in CD8+ T cells and CD56+ NK cell subsets of PBMCs, is likely one key mediator of
this effect in these immune cell subsets.
DUSP6 is a member of the DUSP family that dephosphorylates threonine and tyrosine
residues on MAPK substrates. It specifically dephosphorylates ERK, a member of the
MAPK family that also includes p38 and JNK. MAPKs are activated by growth
factors, cytokines, integrin ligands, and stress signals to regulate growth, survival,
apoptosis, and immune response in diverse cell types. Interestingly, DUSP6 is
expressed at low levels in resting cells and is actually stimulated by ERK activation,
promoting a negative feedback loop on ERK activity [27]. This early response of
DUSP6 to ERK activation could explain the apparently contradictory activation of
ERK by HE4 in cancer cells [14, 16, 17, 23] and our results showing that HE4
upregulation of DUSP6 expression leads to suppression of ERK phosphorylation in
PBMC subsets.
Several reports reveal a role for DUSP6 in development, organogenesis, and cancer
[27]. However, its effect on cancer progression is highly dependent upon the type of
cancer and even the stage. For example, in pancreatic cancer, it is upregulated in early
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stages but is often completely diminished as the tumor progresses towards the invasive
ductal carcinoma state [28]. In lung cancer, it has been shown to act as a tumor
suppressor [29]. Conversely, it is upregulated in glioblastoma and HER2-positive
breast cancer [30, 31]. One report found that its downregulation in ovarian cancer
results in hyperactivation of ERK and subsequent chemoresistance [32]. These
discrepancies are likely due to variable deregulation of ERK signaling and
compensatory pathways that are highly context dependent [27]. In contrast to the roles
of the tumor producing DUSP6 on the tumorigenesis, the functions of DUSP6
originated from immune cells have rarely been evaluated.
Even less is known regarding the role of DUSP6 in immune cell function. Other
members of the DUSP family, including DUSP1, DUSP2, and DUSP10, are known to
have roles in immune response [27], and a few reports suggest that DUSP6 does as
well. Elevated DUSP6 was shown to cause downregulation of ERK phosphorylation
in CD4+ T cells in elderly individuals, who have suppressed immune responses [33].
Another report confirmed this age associated rise in CD4+ T cell DUSP6 expression,
and found that young immunosuppressed patients with end stage renal disease have
DUSP6 levels comparable to elderly healthy individuals [34]. One study found that
DUSP6 downregulates ERK activity in CD4+ T cells and increases their regulatory T
cell functions [35]. Together, these reports suggest that higher levels of DUSP6
contribute to immune suppression. It has also been shown that DUSP6 is
downregulated in T cells upon IL-2 withdrawal [36], and IL-2 was found to upregulate
DUSP6 gene expression in T cells [37]. Since IL-2 stimulates cytotoxic T cell
expansion and activation as well as that of immune suppressive regulatory T cells
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[38], it remains to be determined how the IL-2 responsiveness of DUSP6 plays into its
apparent effect on immune suppression, and how this relates to tumor immune
response.
Although much remains unknown regarding the specific effects of DUSP6 on cancer
progression and tumor immunity, our findings begin to reveal some novel insights. We
report for the first time that HE4-mediated upregulation of DUSP6 in CD8+ T cell and
CD56+ NK cell subsets of PBMC cells leads to the inhibition of their cytotoxic
activity against SKOV3 ovarian cancer cells. While DUSP6 has been connected to
immune function of CD4+ T cells, our results reveal that the subsets of lymphocytes
affected by DUSP6 are context dependent. Further investigation into the inhibitory
effects of DUSP6 in these different populations will be illuminating. Moreover, we
have begun to establish HE4 as a critical regulator of immune cell function, which
deepens our understanding of the mechanistic role HE4 plays in ovarian cancer
pathogenesis.
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Figure II.1 HE4 upregulates expression of DUSP6 in PBMCs.
(A) DUSP6 transcription in response to a 6-hour incubation with 0.01 g/mL rHE4
(HE4) or vehicle (CTR) were evaluated by triplicated trials of real time PCR using
PBMCs from four individual donors. (B) Two-color flow cytometric analysis of PBMC
following 24-hr incubation with 0.01 g/mL of rHE4 (HE4) or vehicle (CTR). 2Dscatterplots (upper panel) of DUSP6 (Alexa Fluor 647) and CD3 or CD56 (FITC) are
shown. The lower panel shows bar graph from flow cytometric analyses using PBMCs
from four individual donors. The mean ± SEM are shown. *p<0.05.
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Fig. II.1
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Figure II.2 HE4 upregulates expression of DUSP6 in peripheral CD8+ T cells.
Two-color flow cytometric analysis of PBMCs following 24-hour incubation with
0.01 g/mL of rHE4 (HE4) or vehicle (CTR). 2D-scatterplots (upper panel) of DUSP6
(Alexa Fluor 647) and CD4 or CD8 (FITC) are shown. The lower panel shows a bar
graph from flow cytometric analyses using PBMCs from four individual donors. The
mean using ± SEM are shown. *p<0.01.
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Fig. II.2
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Figure II.3 HE4 suppresses Erk1/2 phosphorylation in CD8+ and CD56+ cells via
DUSP6 induction.
(A) Two-color flow cytometric analysis of PBMC following a 24-hour incubation
with rHE4 (0.01 g /mL) and BCI (1 M) as indicated. 2-D scatterplots of phosphorErk1/2 (Alexa Fluor 647) and CD8 or CD56 (FITC) are shown. Mean ± SEM from
analyses with four individual donors are shown in the bar graph. (B) Immunoblotting
for phosphor-Erk1/2 in CD56+ NK92MI, CD8+ TALL-104 and CD4+ H9 cells
following a 1-hour incubation with the conditioned media from a 24-hour PBMC
culture with rHE4 (0.01 g/mL) and BCI (1 M) in the indicated combinations. Blots
of total Erk1/2 are shown as loading controls. Bar graph represents the relative band
densities to controls. Mean ± SEM are shown (n=4). *p < 0.05, **p < 0.01.
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Fig.II.3
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Figure II.4 Responses of SKOV3 cells to co-culture with PBMCs
(A) Cells were co-cultured with PBMC (5 x 106 / mL) with rHE4 (0.01 g /mL) and
BCI (1 M) in indicated combinations. The cells viabilities were assessed at 24, 48
and 72 hours of the culture (n = 10). (B) Ki67 immunohistochemistry staining was
performed on SKOV3 cells co-cultured with PBMC for 24 hours. Ki67+ cells are
identified with red nuclear staining. Bar graph represents the percentage of Ki67+
cells in total countable cells under 200x fields (n = 20). (C) Two-color flow cytometric
analysis of SKOV3 following 6-hour PBMC co-culture with of rHE4 (0.01 g/mL)
and BCI (1 M) as indicated. 2D-scatterplots of propidium iodide and annexin V
(Alexa Fluor® 488) are shown. Bar graph represents the percentage of propidium
iodide / annexin V double positive cells in total cells (n = 4). Mean ± SEM are shown
in the bar graphs. *p < 0.01.
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Fig.II.4
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Figure II.5
Responses of SKOV3 cells to co-culture with CD8+ / CD56+ cell free PBMCs
(A) Cells were co-cultured with CD8+ / CD56+ cell-free PBMCs with rHE4 (0.01 g
/mL) and BCI (1 M) in indicated combinations. The cells viabilities were assessed at
24, 48 and 72 hours of the culture (n = 10). (B) Ki67 immunohistochemistry staining
was performed on SKOV3 cells co-cultured with CD8+ / CD56+ cell-free PBMCs for
24 hrs. Ki67+ cells are identified with red nuclear staining. Bar graph represents the
percentage of Ki67+ cells in total countable cells under 200x fields (n = 20). (C) Twocolor flow cytometric analysis of SKOV3 following 6 -hour CD8+ / CD56+ cell free
PBMCs co-culture with of rHE4 (0.01 g/mL) and BCI (1 M) as indicated. 2Dscatterplots of propidium iodide and annexin V (Alexa Fluor® 488) are shown. Bar
graph represents the percentage propidium iodide / annexin V double positive cells in
total cells (n = 4). Mean ± SEM are shown in the bar graphs. *p < 0.01.
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Fig.II.5
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Table II.1 Genes induced in response to HE4

Frequency ID

gene name

23 NSS
3 NG_033915

no significant similarity
dual specificity phosphatase 6 (DUSP6)
capping actin protein of muscle Z line alpha sub
3 XM_017002424
unit 1 (CAPZA1)
eukaryotic translation elongation factor 1 alpha 1
3 NM_001402
(EEF1A1)
FGR proto-oncogene, Src family tyrosone kinase
3 XM_017000674
(FGR)
3 NM_001261446.1 thioredoxin reductase 1 (TXNRD1)
3 NM_021109
thymosin beta 4, X-linked (TMSB4X)
3 BC006364
tubulin folding cofactor D
2 AK223032
beta actin variant
2 AC008397.7
chromosome 19 clone CTC-251H24
2 NM_001170330
chromosome 4 open reading frame 3 (C4orf3)
2 AY430097
DAZ associated protein 2 (DAZAP2)
2 NM_001005360
dynamin 2 (DNM2)
eukaryotic translation elongation factor 1 alpha 1
2 NG_002350.4
pseudogene 5 (EEF1A1P5)
2 NM_004468.4
four and a half LIM domains 3 (FHL3)
2 NM_001077488
GNAS complex locus (GNAS)
2 NM_001321232
histocompatibility (minor) HA-1 (HMHA1)
2 NM_000206.2
interleukin 2 receptor, gamma (IL2RG)
2 NM_001127605.2 lipase A, lysosomal acid (LIPA)
2 NM_012335.3
myosin IF (MYO1F)
2 XM_011541520
notch 2 (NOTCH2)
nuclear factor of kappa light polypeptide gene
2 NM_001165412
enhancer in B-cells 1 (NFKB1)
phosphatidylinositol-3,4,5-trisphosphate
2 NM_020820.3
dependent Rac exchange factor 1 (PREX1)
phosphoinositide-3-kinase regulatory subunit 5
2 NM_001251855
(PIK3R5)
2 NM_201384.2
plectin (PLEC)
2 NM_002952
ribosomal protein S2 (RPS2)
2 NM_001007.4
ribosomal protein S4, X-linked (RPS4X)
2 NM_000655
selectin L (SELL)
2 NM_004252
SLC9A3 regulator 1 (SLC9A3R1)
2 NM_022733.2
small ArfGAP2 (SMAP2)
2 NM_001278206
solute carrier family 43, member 3 (SLC43A3)
2 NM_025250.2
tweety family member 3 (TTYH3)
2 BC050652.1
zinc finger, DHHC-type containing 16
2 NM_004773
zinc finger, HIT-type containing 3 (ZNHIT3)
2 XM_011516569
zyxin (ZYX)
1
154 genes
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Table II.2 DUSP6 concentration in cell lysates and culture media of PBMCs
Cell lysates*
Culture media**
CTR
HE4
CTR
HE4
9.38 ± 0.62
15.62 ± 0.97***
0.77 ± 0.10
1.43 ± 0.14***
*I 2.5 mg/mL of total protein(ng/mL)
**in 5 mL media of 5 x 106 PBMC culture
The mean ± are shown, n = 10 / each group, ***< 0.01 vs CTR
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III.1 Abstract
Dual Specificity phosphatase 6 (DUSP6) is a phosphatase that deactivates
extracellular-signal-regulated kinase (ERK). Since the ovarian cancer clinical
biomarker human epididymis protein 4 (HE4) has been shown to interact with the
ERK pathway, the objective of this study was to determine the relationship between
DUSP6 and HE4 and begin to elucidate the role of DUSP6 in epithelial ovarian cancer
(EOC). Western blot and quantitative PCR following knockdowns showed that HE4
and DUSP6 levels were reduced with knockdown of the other protein in SKOV3 and
OVCAR8 ovarian cancer cells. Furthermore, DUSP6 levels were upregulated in cells
overexpressing HE4. Since HE4 has been shown to promote chemoresistance in EOC,
the effect of DUSP6 on chemotherapeutic response was evaluated. MTS assay
revealed a significant decrease in cell viability with pharmacological inhibition of
DUSP6 using BCI in cells treated with carboplatin or paclitaxel, compared to
treatment with single-agent chemotherapy alone. Quantitative PCR was used to
evaluate gene expression responses to BCI, recombinant HE4 (rHE4), carboplatin,
paclitaxel, and combinatorial treatments. DUSP6 inhibition with BCI altered
expression of ERK pathway response genes, including early growth response protein 1
(EGR1) and c-Jun. Expression of EGR1, a strong promotor of apoptosis, was higher in
ovarian cancer cells co-treated with BCI and paclitaxel or carboplatin than in cells
treated with chemotherapeutic agent alone. Alternatively, the expression of c-Jun, a
proto-oncogene, decreased with co-treatment of BCI and paclitaxel or carboplatin. The
effect of BCI on the expression of these two genes opposed the effect of rHE4 on their
expression. Finally, expression levels of DUSP6 in EOC tissue were evaluated by
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immunohistochemical staining and quantification of mean and maximum intensity or
integrated optical density (IOD). Levels of DUSP6 were noted to be significantly
upregulated in serous EOC tissue compared to adjacent normal tissue, and a positive
correlation between HE4 and DUSP6 levels was observed by Spearman Rank
correlation. Unpaired 2-tailed student t-test was employed to determine statistical
significance of results. In conclusion, DUSP6 inhibition sensitizes ovarian cancer cells
to chemotherapeutic agents and alters gene expression of ERK response genes. The
ability to detect HE4 levels in EOC patients coupled with the established codependence of DUSP6 with HE4, indicates that DUSP6 could plausibly function as a
novel therapeutic target in EOC.
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III.2 Introduction
Epithelial ovarian cancer (EOC) remains the most common and deadly gynecologic
cancer, responsible for 240,000 diagnoses and 152,000 deaths worldwide each year
[1]. The 5-year survival rate remains at 35% [2], which is largely due to difficulty with
early diagnosis, coupled with the frequency of chemoresistant recurrences [3].
Although a majority of EOC is initially responsive to chemotherapy, once the disease
recurs, chemoresistance inevitably develops and the patient eventually will succumb to
their illness [4]. Therefore, there is a need for improved diagnostic approaches, as well
as novel treatment targets to combat chemoresistance.
Human epididymis protein 4 (HE4) has been established as a novel clinical biomarker
for EOC. Inclusion of preoperative levels of HE4 into the diagnostic Risk of Ovarian
Malignancy Algorithm (ROMA) results in demonstrably improved specificity and
sensitivity in detection and monitoring of the disease over Cancer Antigen 125 (CA
125), pelvic sonography, and menopausal status [5]. Research has also shown its
mechanistic involvement in promoting EOC pathogenesis, including the promotion of
proliferation, chemoresistance, anti-estrogen resistance, adhesion, invasion, and
migration [6–16]. One oncogenic pathway that has been shown to interact with HE4 in
several studies is the extracellular signal regulated kinase (ERK) pathway. Several
reports indicate that ERK activation is enhanced with HE4 treatment or
overexpression, while ERK activation is reduced with HE4 knockdown [8, 14, 15].
Our lab has revealed a more complicated response of ERK to recombinant HE4
treatment; specifically, we have observed downregulation of ERK phosphorylation at
early time points, and upregulation at later time points [8]. Although the exact
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mechanism of HE4 interaction with the ERK pathway is not clarified, it is well
established that HE4 mediates ERK activation in EOC.
Dual specificity phosphatase 6 (DUSP6) is a key negative regulator of ERK signaling
via dephosphorylation of ERK at serine/tyrosine residues. ERK activation upregulates
gene expression of DUSP6, which promotes a negative feedback loop on ERK
activation [17]. DUSP6 has been shown to have differing effects on tumor progression
depending on the tumor type. In pancreatic cancer, it is initially upregulated, but
diminished at later stages, and is considered a tumor suppressor [18]. It is also
considered a tumor suppressor in lung cancer [19]. However, in glioblastoma and
HER-2 positive breast cancer, it has been shown to be upregulated [20, 21]. In gastric
cancer, DUSP6 inhibition can overcome chemoresistance [22], and it has also been
characterized as a therapeutic target in acute lymphoblastic leukemia [23]. One study
in ovarian cancer suggested that it may act as a tumor suppressor [24]. The goal of the
present study was to determine the relationship between HE4 and DUSP6 in EOC and
begin to elucidate the role of DUSP6 in EOC.

III.3 Methods
Cell Culture, Treatments, and siRNA Knockdowns
SKOV3 and OVCAR8 cells were obtained from ATCC and cultured in Dulbecco
Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 1%
penicillin/streptomycin, in a humidified incubator at 37°C/5% CO2. Cells were plated
at sub-confluent density the day before treatments. Cells were treated with 3.75 µM
BCI (Sigma, B4313), 20 nM recombinant HE4 (My BioSource, MBS355616), 100-
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500 µM carboplatin (Sigma Aldrich, C2538), 10 nM paclitaxel (Sigma Aldrich,
T7402), or control treatments (.037% DMSO and/or H20) for indicated time points.
Knockdowns were performed using siRNA directed against DUSP6 (Santa Cruz, sc39000), HE4 LNA GapmeRs (Exiqon, 300600 Design ID 414262-1), control nontargeting siRNA (Santa Cruz, sc-37007) or Negative Control GapmeRs (Exiqon,
300610). Five µL lipofectamine 2000 (Invitrogen, 52887) was incubated at room
temperature in 100 µL serum/antibiotic free DMEM. Meanwhile, siRNA was
incubated separately in 100 µL serum/antibiotic free medium at a concentration of 2
µM for 5 minutes. The tubes were combined and incubated at room temperature for 20
minutes. The complex was added to cells cultured in DMEM with serum but no
antibiotic to a final concentration of 100 nM. Cells were collected or underwent
additional treatments after 48 hours.

Western Blot
Western blot was performed as previously described [9]. GAPDH was used as a
loading control. Antibodies and dilutions used are as follows:
DUSP6 (MyBioSource, MBS8516662, 1:500)
HE4 (Santa Cruz, sc-293-473, 1:200)
GAPDH (Cell Signaling, 2118, 1:2000)
Phospho-ERK (Cell Signaling, 1:2000)
ERK (Cell Signaling, 1:2000)
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Densitometry
Image J “analyze gel” function was used to perform densitometry analysis of western
blot images in 8-bit TIFF format. Band densities were normalized to GAPDH, and the
lowest value was set to 1 for plotted graphs.

Quantitative RT-PCR
Quantitative RT-PCR was performed as previously described [9]. Validated primers
for DUSP6, EGR1, and c-JUN were purchased from realtimeprimers.com. Custom
primer sequences (Invitrogen) are as follows:
18s rRNA (F) – CCG CGG TTC TAT TTT GTT GG
18s rRNA (R) – GGC GCT CCC TCT TAA TCA TG

Cell Viability Assay
Cells were seeded at 2 000 cells/well in 96-well plates and treated as described above.
After 48 h, cell viability assays were performed by adding 10 µl/well of CellTiter 96®
Aqueous One Solution Cell Proliferation MTS Assay (Promega, G3580), incubating at
37°C/5% CO2 for 2 h, and reading absorbance at 492 nm. Results are displayed as
percent survival of vehicle treated cells.

Immunohistochemistry
Immunohistochemical staining of an ovarian cancer microarray (US Biomax,
OV802a) and patient tissues from the Women & Infants Pathology Department was
performed as previously described [35], using antibodies for HE4 (Santa Cruz, sc-
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293473), DUSP6 (MyBioSource, MBS8516662). Confocal microscopy was
performed by an independent imaging technician at the Rhode Island Hospital Digital
Imaging Core Facility with a Nikon C1si confocal (Nikon Inc. Mellville, NY, USA).
Two to three fields/sample were randomly selected based on DAPI staining, and
minimum, mean, and maximum gray values were determined for each field. For the
tumor microarray, normal adjacent tissues were used to set the threshold for positive
staining. Integrated optical density (IOD) was calculated in serous samples using the
mean values multiplied by the total area.

Statistics
Where statistics are shown, n≥3 biological replicates. Error bars represent standard
deviation (STDEV) for quantitative PCR and MTS results, and standard error of the
mean (SEM) for immunohistochemistry results. P-values were determined by
unpaired, 2-tailed Student t-test. For correlation analysis, Spearman rank test was used
to determine R value. Differences were considered statistically significant when p <
0.05.

III.4 Results
HE4 and DUSP6 Levels Are Co-Dependent in Ovarian Cancer Cell Lines
We first confirmed the upregulation of DUSP6 by HE4 by examining mRNA and
protein levels in SKOV3 and OVCAR8 ovarian cancer cells stably overexpressing
HE4 (clone 1 and clone 5, respectively) or their null vector (NV) counterparts. DUSP6
mRNA was upregulated by HE4 overexpression (1.2)-fold (p<0.05) and (3.9)-fold
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(p<0.05), in SKOV3 and OVCAR8 cells, respectively (Figure 1A-B). To determine
the reciprocity of the relationship between HE4 and DUSP6, we performed transient
siRNA knockdown of DUSP6 and LNA GapmeR knockdown of HE4. We observed
that knockdown of HE4 protein resulted in a corresponding downregulation of
DUSP6, and knockdown of DUSP6 resulted in a corresponding downregulation of
HE4 (Figure 1C-F).

Inhibition of DUSP6 Sensitizes Ovarian Cancer Cells to Chemotherapeutic Drugs
Next, we wanted to begin to determine the function of DUSP6 in ovarian cancer cells.
Since one well-known role of HE4 in EOC is the promotion of chemoresistance, we
treated SKOV3 and OVCAR8 cells with a DUSP6 inhibitor (BCI) alone or in
combination with paclitaxel or carboplatin, the standard of care chemotherapeutic
agents in EOC. Treatment of cells with BCI alone resulted in a small but significant
reduction in cell viability as determined by MTS assay – 86.3% and 84.7% in
OVCAR8 and SKOV3, respectively. In both cell lines, co-treatment with BCI and
carboplatin resulted in a synergistic effect on cytotoxicity compared to either treatment
alone. Carboplatin alone treatment resulted in 89.8% and 86.8% survival in OVCAR8
and SKOV3 cells, respectively, while BCI with carboplatin resulted in 33.9% and
50.2% survival in OVCAR8 and SKOV3 cells, respectively. In OVCAR8 cells, a
synergistic effect was noted with BCI and paclitaxel treatment as well, with survival
reducing from 51.4% with paclitaxel alone to 25.3% with BCI and paclitaxel (Figure
2A-B).
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DUSP6 Inhibition Alters Expression of ERK Pathway Responsive Genes
In order to determine how regulation of ERK signaling by BCI versus rHE4 might
affect downstream gene expression, we treated cells with BCI alone or in combination
with rHE4, paclitaxel, or carboplatin, and examined expression of the ERK pathway
response genes EGR1 and c-Jun. EGR1 is a transcription factor involved in promoting
apoptosis in many cancers [25–28], and has been shown to be involved in cisplatin
resistance in esophageal and ovarian cancers [29, 25]. We have previously shown that
HE4 suppresses EGR1 gene upregulation in response to cisplatin treatment of SKOV3
cells [8]. On the other hand, c-Jun is an AP-1 transcription factor involved in
promoting cell survival and growth [30, 31]. Treatment with BCI modestly
upregulated EGR1 expression in both cell lines, while treatment with rHE4
downregulated EGR1 expression—a result that is in agreement with our previous
study showing HE4 suppresses cisplatin-mediated upregulation of EGR1. The effect
of BCI on EGR1 expression was more apparent with rHE4 co-treatment, where it
reversed the downregulation of EGR1 by rHE4. Furthermore, co-treatment with BCI
and either paclitaxel or carboplatin upregulated expression of EGR1 compared to
treatment with either chemo drug alone. These results show that BCI opposes the
effects of HE4 on EGR1 expression and promotes EGR1 expression while suppressing
c-Jun expression in cells exposed to chemotherapy drugs (Figure 3A-D).
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DUSP6 Levels Are Upregulated in EOC Tissue Compared to Adjacent Normal Tissue,
and Correlate with HE4 Tissue Levels
To verify the clinical relevance of our findings, we performed immunohistochemistry
of DUSP6 in an EOC tumor microarray and compared levels in serous
adenocarcinoma samples (n=40) to levels in normal adjacent tissue (NAT; n=7). Mean
intensity of DUSP6 was 545 (+/- 24.5) in EOC samples, and 432 (+/-19.6) in NAT
(p=0.005). Moreover, maximal intensity was significantly greater in serous EOC
samples than NAT. Maximum intensity was 1653 (+/-75.3) for EOC and 900 (+/110.3) for NAT (p=0.016), indicating that some areas of EOC exhibited particularly
strong staining for DUSP6 (Figure 4A). Representative images are shown in Figure
4B.
In order to determine if a correlation exists between HE4 levels and DUSP6 levels in
EOC, we co-stained for both proteins in the ovarian tissue microarray, and calculated
correlations for mean intensity values and integrated optical density (IOD). Spearman
Rank correlation test revealed a positive correlation between DUSP6 and HE4 mean
intensities (R=0.45, p=0.0038) and IOD values (R=0.64, p=0.00001) (Figure 4C-D).
Together, these results suggest that DUSP6 may be involved in promoting
tumorigenesis in EOC, and corroborate our results indicating a relationship between
HE4 and DUSP6.

III.5 Discussion
In this study, we have determined that HE4 and DUSP6 levels are co-dependent in
ovarian cancer cells, and that these two proteins interact and are correlated in patient
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tissue. Future studies are needed to elucidate the exact mechanistic relationship
between DUSP6 and HE4. Studies by us and others have confirmed that HE4 activates
ERK in ovarian cancer cells [8, 14, 15], while DUSP6 is a known negative regulator
of ERK signaling [17]. Interestingly, despite the fact that HE4 and DUSP6 have
opposing roles on ERK activation, they appear to produce similar effects on biological
function of tumor cells. Our results show that activation of ERK by the DUSP6
inhibitor BCI as opposed to HE4 produces very different effects on gene expression
and cellular functions such as chemotherapy response.
The two ERK responsive genes we have characterized show opposite expression
patterns with BCI treatment. EGR1 is activated by ERK via the transcription factor
ELK-1, and EGR1 is itself a transcription factor that activates expression of proapoptotic genes [32]. A previous study by our lab showed that HE4 overexpression in
SKOV3 cells suppresses cisplatin-mediated upregulation of EGR1 [8]. Here, we
observe that HE4 downregulates EGR1 expression, which is consistent with these
previous results. Conversely, BCI treatment opposes the effect of rHE4 on EGR1
expression, indicating differing effects downstream of ERK activation by these two
treatments. C-Jun, which is also an ERK responsive gene, is regulated oppositely as
EGR1. rHE4 treatment upregulates expression of c-Jun, which is consistent with its
role as a promoter of tumor growth and proliferation [6, 12, 13, 33, 34]. Meanwhile,
BCI again opposes this effect in BCI and rHE4 co-treated cells. Furthermore, BCI
suppresses chemotherapy-mediated increases in c-Jun levels. The effects of BCI on
EGR1 and c-Jun together may contribute to the overall increased efficacy of BCI and
chemotherapy treatment over chemotherapy alone.
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The role of DUSP6 in EOC is not well studied. One report showed that DUSP6
appears to function as a tumor suppressor in EOC [24], but our results suggest the
opposite effect. Therefore, further study is needed to fully elucidate the role of DUSP6
and determine if its function is context dependent. In general, DUSP6 remains an
interesting protein, in that it has opposing roles in different tumor types. In some
cancers, it appears to act as a tumor suppressor, while in others it acts to promote
tumorigenesis and aggressive behavior [19–24]. Our results are consistent with a
recent study by Wu et al. (2018) showing its involvement in cisplatin resistance in
gastric cancer [22]. The authors observed an increase in phospho-ERK with BCI
treatment, but a downregulation of the ERK-response genes RPS6KA1, EGR1,
MMP2, MMP9, MYC, and ELK3. Furthermore, they found that BCI treatment
enhanced cisplatin sensitivity in gastric cancer cells and in vivo xenografts. In our
study, we observed different effects of DUSP6 inhibition on ERK-response genes
depending upon gene function—namely, upregulation of the tumor suppressor EGR1
and downregulation of the proto-oncogene c-Jun. Collectively, our study and the one
by Wu et al. illustrate that the relationship between ERK activation and downstream
gene activation is not straightforward and appears to be highly context-dependent.
Therefore, although BCI serves to increase ERK activation, it has different effects on
ERK response genes, which serve to enhance chemotherapy efficacy.
In conclusion, this study highlights a novel function of DUSP6 in EOC and reveals
that it may be involved in regulating chemoresponse. Targeting HE4 and/or DUSP6 in
EOC may be an effective method of reversing chemoresistance and improving longterm response rates in select patient populations.
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Figure III.1 HE4 and DUSP6 Levels are Co-Dependent in Ovarian Cancer Cell Lines
DUSP6 mRNA levels are higher in SKOV3-C1 (A) and OVCAR8-C5 (B) cells
overexpressing HE4 than in null vector (NV) cells. *p<.05 (C) HE4 protein levels are
reduced in cells with DUSP6 knockdown. (D) DUSP6 protein levels are reduced with
HE4 knockdown.
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Figure III.2 Inhibition of DUSP6 Sensitizes Ovarian Cancer Cells to
Chemotherapeutic Drugs.
(A) SKOV3 cells exhibited reduced viability when co-treated with the DUSP6
inhibitor BCI and either paclitaxel or carboplatin compared to either chemotherapeutic
agent alone. (B) SKOV3 cells exhibited reduced viability when co-treated with the
DUSP6 inhibitor BCI and either paclitaxel or carboplatin compared to either
chemotherapeutic agent alone. Error bars represent standard deviation of 3 biological
replicates in a single experiment. *p<0.05, ***p<.0005, ****p<.00005
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Figure III.3 DUSP6 Inhibition Alters Expression of ERK Pathway Responsive Genes.
(A-B) BCI opposes the effect of rHE4 on EGR1 levels in OVCAR8 and SKOV3 cells.
EGR1 mRNA levels are higher in cells co-treated with BCI and chemotherapeutic
drugs than in cells treated with chemotherapy alone. (C-D) BCI opposes the effect of
rHE4 on EGR1 levels in OVCAR8 and SKOV3 cells. JUN mRNA levels are lower in
cells co-treated with BCI and chemotherapeutic drugs than in cells treated with
chemotherapy alone. n=2-3 independent experiments.
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Fig.III.3
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Figure III.4
Figure 4. DUSP6 Levels are Higher in EOC Tissue than Normal Adjacent Tissue, and
Correlate with HE4 Tissue Levels.
(A) DUSP6 mean and maximum intensity staining is higher in serous EOC tissue
(n=40) than in normal adjacent tissue (NAT) (n=7). Error bars represent deviation.
*p<0.05 (B) Representative images of NAT and serous EOC DUSP6 staining. (C)
Correlation of DUSP6 and HE4 mean intensity. (D) Correlation of DUSP6 and HE4
integrated optical density (IOD). Graph excludes one outlier data point for clarity (data
is included in Spearman Rank Correlation calculation).
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IV.I Abstract
Epithelial Ovarian Cancer (EOC) is associated with dismal survival rates due to the
fact that patients are frequently diagnosed at an advanced stage and eventually become
resistant to traditional chemotherapeutics. Hence, there is a crucial need for new and
innovative therapies. Septin-2, a member of the septin family of GTP binding proteins,
has been characterized in EOC for the first time and represents a potential future
target. Septin-2 was found to be overexpressed in serous and clear cell human patient
tissue compared to benign disease. Stable septin-2 knockout clones developed in an
ovarian cancer cell line exhibited a significant decrease in proliferation rates.
Comparative label-free proteomic analysis of septin-2 knockout cells revealed
differential protein expression of pathways associated with the TCA cycle, acetyl
CoA, proteasome and spliceosome. Further validation of target proteins indicated that
septin-2 plays a predominant role in post-transcriptional and translational
modifications as well as cellular metabolism and are the first to suggest the potential
novel role of septin-2 in promoting EOC tumorigenesis through these mechanisms.
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IV.2 Introduction
Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic malignancy [1]. In
2018, there will be an estimated 22,240 new cases of EOC diagnosed and 14,070
deaths in the United States. While EOC accounts for only 2.5 % of all female cancers,
it is responsible for 5% of all cancer deaths due to low disease survival rates [2].
These dire statistics are attributed to the fact that the majority of patients are diagnosed
at an advanced stage. In addition, while patients generally respond well to frontline
platinum-based chemotherapy, chemoresistant recurrences are common [3]. Therefore,
there is a strong need for novel early detection methods and targeted therapies for
EOC patients.
Septin-2 is a member of the septin family, a conserved family comprised of 13 GTP
binding proteins [4]. Septins, which are structurally observed as rods and filaments,
are vital to a number of cellular processes, including cytokinesis, vesicle trafficking,
and exocytosis [5]. They are considered to be a fourth component of the cytoskeleton
due to their association with actin, microtubules, and membranes [6]. Septins have
been identified as having a role in neurodegenerative disease, since they were detected
in brain tissue from patients with Alzheimer disease [7]. In addition, they have been
reported to be involved in bacterial infections, Parkinson’s disease, and male infertility
[8].
In more recent years, emphasis has been placed on investigating the role of septins in
tumorigenesis [9]. Due to their natural function in scaffolding and membrane
compartmentalization, it is plausible that they could also play a role in the
organization of membrane associated proteins involved in diverse tumorigenic

159

signaling pathways [6]. Septin-9 is the best studied septin family member in
relationship to cancer, and its methylation status is utilized as a biomarker in
colorectal cancer [10]. However, there have also been numerous studies linking
septin-2 to neoplasia. Thus far, septin-2 has been specifically implicated in Hodgkin’s
lymphoma and biliary tract, gastric, hepatocellular, and breast cancer [11–15], but its
role in EOC has not yet been investigated.
In this study, we begin to elucidate septin-2’s function in EOC. As septins have been
shown to have diverse roles in tumorigenesis, this is the first step in specifically
defining septin-2’s contribution to EOC pathogenesis. To establish the clinical
relevance of septin-2 in EOC, we first sought to compare levels of septin-2 in various
histological pathologies of EOC versus benign disease. Furthermore, we present for
the first time a global analysis of septin-2 mediated proteomics in EOC and describe
signaling pathways most affected by septin-2 depletion. The results from this study lay
the framework for future mechanistic studies to determine the precise role of septin-2
in EOC.

IV.3 Methods
Cell Culture
SKOV3 wild type (SKOV3WT) and OVCAR8 wild type (OVCAR8WT) cell lines
were obtained from American Type Culture Collection (ATCC) and were cultured in
Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin in a humidified incubator at 37°C/5% CO2.

160

Septin-2 silencing with shRNA
shRNA for human HE4 (Santa Cruz Biotechnology, sc-40936-SH) or control shRNA
(Santa Cruz Biotechnology, sc-108066) was transfected into SKOV3WT cells using
Lipofectomine® 2000 (Invitrogen, 11668) following the manufacturer’s instructions.
Individual single cells were selected by culturing under the pressure of 5 ug/mL of
puromycin (Research products International, 58-58-2), and clonal populations were
allowed to expand. Phenotypes of the clones were evaluated by western blotting using
anti Septin-2 antibody (Novus Biologicals, NBP1-85212)

Proliferation Assay
SKOV3WT, Plasmid C, KO#9, and KO#11 were plated at equal densities in
100x20mm plates. Cells were trypsinized at 72 and 96 hours, and replicates of three
were counted using a hemocytometer to compare proliferation rates. The experiment
was repeated three times and error bars represent standard deviation. Statistical
significance was determined by an unpaired, two-tailed Student t-test, where p<.05
was considered significant.

Immunohistochemistry and confocal immunofluorescent microscopy
Formalin-fixed paraffin embedded human ovarian tissue slides were obtained from the
Women and Infants Pathology Department. The human ovarian tissue microarray was
obtained from US Tissue Biomax (OV802a). Slides obtained from Women and Infants
were baked at 65 °C for two hours, and the microarray for 20 minutes. All slides were
subsequently washed in xylene, 100% ethanol, 95% ethanol, 70% ethanol,
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deoxygenated water, and FTA Hemagglutination Buffer. Antigen retrieval was then
performed using DAKO antigen retrieval solution (10x) (Agilent, S1699), heated to 95
°C for 20 minutes. Slides were then blocked with 5% horse serum in FTA
Hemagglutination Buffer and incubated overnight in primary Septin-2 antibody (Santa
Cruz, sc-20408) at 4 °C. Secondary antibody, Alexa Fluora 488 (Thermo Fisher
Scientific, A-11055) was then added to slides following incubation in the dark for one
hour at room temperature. Slides were washed in between steps with FTA
Hemagglutination Buffer and were cover-slipped with DAPI containing mounting
medium (Vector Laboratories, H-1200). Images were acquired using a Nikon E800
microscope (Nikon Inc. Mellville, NY, USA) and an RT3 SPOT camera (Diagnostic
Istruments, Sterling Heights, MI, USA). Random sampling of ten fields was based on
DAPI staining. Mean intensity or integrated optical density (IOD), expressed as
area*mean/1E+07, was acquired using a 40X objective. Statistical significance was
determined by an unpaired, two-tailed Student t-test, where p<.05 was considered
significant.

Western Blot
Protein was extracted from cell pellets in Cell Lysis Buffer (Cell Signaling, 9803) with
1 mM of PMSF, according to the manufacturer’s protocol. The concentration of
extracted proteins was determined by DC Protein Assay (Bio-Rad Laboratories,
5000116). Western blot analysis was performed by loading equal amounts of protein
boiled at 70 °C with Novex Sample Reducing Agent (Life Technologies, NP009) and
NuPAGE LDS sample buffer (ThermoFisher Scientific, NP0007) into a 4–12 %
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gradient NuPAGE Novex Bis-Tris gel [Life Technologies, NP0321BOX (mini),
WG1402BX10 (midi)]. The gel was then transferred using a semi-dry transfer to
methanol-activated 0.2 μm PVDF membranes (Bio-Rad, 162-0177) at 0.12-0.24A for
1 h 20 m. Membranes were blocked in 5 % milk in phosphate-buffered saline with
0.05 % Tween 20 (PBS-T) for 30 m at room temperature. Finally, membranes were
incubated in primary antibody diluted in 5 % milk in PBS-T overnight at 4 °C, and
then in secondary antibody diluted in 5 % milk in PBS-T for 1 h at room temperature,
with PBS-T washes in between. Amersham ECL Prime Western Blot Detection
System (GE Healthcare, RPN2232) was employed for detection of the HRP-tagged
secondary antibodies. The Biorad Chemidoc MP Imaging System was used to image
all blots. GAPDH was used as a loading control. Antibodies and respective dilutions
used are as follows:
GAPDH (cell signaling, 2118, [1:2000])
Septin-2(novus biologicals, NBP1-85212, [1:500])
LDHA(cell signaling, 3582S, [1:1000])
FASN (cell signaling, 3180S, [1:1000])
Enolase (santa cruz biotechnology, sc-100812 [1:500])
Transketolase (santa cruz biotechnology, sc-390179) [1:500])

Quantitative PCR
RNA was extracted from cells by Trizol /LiCl precipitation. Total RNA (1000 ng) was
then reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad,
1708890), following the manufacturer’s protocol. Quantitative PCR was performed in
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triplicate by loading 1 μl cDNA reaction, 1 μM forward and reverse validated Septin-2
primers (Origene HP232247), 10 μl SYBR Green (Applied Biosciences [ABI],
4367659) and 5 μl RNAse-free water to each well. Samples were run using the ABI
7500 Fast Real-Time PCR System. Data was then analyzed using the ΔΔCt method.
All gene expression levels were normalized to 18 s rRNA.

Densitometry
Densitometry analysis of western blots was performed using image J. Blot images
were analyzed in 8-bit JPEG format, using the “analyze gel” function. Relative band
densities were normalized to GAPDH loading control.

Sample preparation for LC-MS/MS analysis
Cell pellets were subjected in lysis buffer (8 M urea, 1 mM sodium orthovanadate, 20
mM HEPES, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, pH 8.0, 20
min, 4°C), sonicated and cleared by centrifugation (14 000 × g, 15 min, 4°C). Protein
concentration was measured (Pierce BCA Protein Assay, Thermo Fisher Scientific, IL,
USA) and a total of 100 µg of protein per sample was subjected for trypsin digestion.
Typtic peptides were desalted using C18 Sep-Pak plus cartridges (Waters, Milford,
MA) and were lyophilized for 48 hours to dryness. The dried eluted peptides were
reconstituted in buffer A (0.1 M acetic acid) at a concentration of 1 µg/µl and 5 µl was
injected for each analysis.
The LC-MS/MS was performed on a fully automated proteomic technology platform
[16,17] that includes an Agilent 1200 Series Quaternary HPLC system (Agilent
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Technologies, Santa Clara, CA) connected to a Q Exactive Plus mass spectrometer
(Thermo Fisher Scientific, Waltham, MA). The LC-MS/MS set up was used as
described earlier [18]. Briefly, the peptides were separated through a linear reversedphase 90 min gradient from 0% to 40% buffer B (0.1 M acetic acid in acetonitrile) at a
flow rate of 3 µl /min through a 3 µm 20 cm C18 column. The electrospray voltage of
2.0 kV was applied in a split flow configuration, and spectra were collected using a
top-9 data-dependent method. Survey full scan MS spectra (m/z 400-1800) were
acquired at a resolution of 70,000 with an AGC target value of 3×106 ions or a
maximum ion injection time of 200 ms. The peptide fragmentation was performed via
higher-energy collision dissociation with the energy set at 28 NCE. The MS/MS
spectra were acquired at a resolution of 17,500, with a targeted value of 2×104 ions or
a maximum integration time of 200 ms. The ion selection abundance threshold was set
at 8.0×102 with charge state exclusion of unassigned and z =1, or 6-8 ions and
dynamic exclusion time of 30 seconds.

Bioinformatics analysis
Peptide spectrum matching of MS/MS spectra of each file was searched against a
species-specific databases (UniProt; downloaded 2/1/2015) using MASCOT v. 2.4
(Matrix Science, Ltd, London, UK). A concatenated database containing “target” and
“decoy” sequences was employed to estimate the false discovery rate (FDR) [19].
Msconvert from ProteoWizard (v. 3.0.5047), using default parameters and with the
MS2Deisotope filter on, was employed to create peak lists for Mascot. The Mascot
database search was performed with the following parameters: trypsin enzyme
cleavage specificity, 2 possible missed cleavages, 10 ppm mass tolerance for precursor
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ions, 20 mmu mass tolerance for fragment ions. Search parameters permitted variable
modification of methionine oxidation (+15.9949 Da) and static modification of
carbamidomethylation (+57.0215 Da) on cysteine. The resulting peptide spectrum
matches (PSMs) were reduced to sets of unique PSMs by eliminating lower scoring
duplicates. To provide high confidence, the Mascot results were filtered for Mowse
Score (>20). Peptide assignments from the database search were filtered down to a 1%
FDR by a logistic spectral score as previously described [19,20].

Relative quantitation of the identified peptides
Relative quantification of peptide abundance was performed via calculation of
selected ion chromatograms (SIC) peak areas. Retention time alignment of individual
replicate analyses was performed as previously described [21]. Peak areas were
calculated by inspection of SICs using in-house software programmed in R 3.0 based
on the Scripps Center for Metabolomics’ XCMS package (version 1.40.0). This
approach performed multiple passes through XCMS’ central wavelet transformation
algorithm (implemented in the centWave function) over increasingly narrower ranges
of peak widths and used the following parameters: mass window of 10 ppm, minimum
peak widths ranging from 2 to 20 seconds, maximum peak width of 80 seconds, signal
to noise threshold of 10 and detection of peak limits via descent on the nontransformed data enabled. SIC peak areas were determined for every peptide that was
identified by MS/MS. In the case of a missing MS/MS for a particular peptide, in a
particular replicate, the SIC peak area was calculated according to the peptide's
isolated mass and the retention time calculated from retention time alignment. A
minimum SIC peak area equivalent to the typical spectral noise level of 1000 was
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required of all data reported for label-free quantitation. Individual SIC peak areas were
normalized to the peak area of the standard synthetic peptide DRVYHPF that was
exogenously spiked prior to reversed-phase elution into the mass spectrometer.
Quantitative analysis was applied to replicate experiments. To select peptides that
show a statistically significant change in abundance between control vs treatment
cells, q-values for multiple hypothesis tests were calculated based on p-values from
two-tailed unpaired Student’s t tests using the R package QVALUE as previously
described [22,23].

IV.4 Results
Septin-2 is overexpressed in EOC
A preliminary proteomic study determined interacting partners of the clinical EOC
biomarker HE4. It was noted that septin-2 was the most upregulated HE4-interacting
protein (13-fold) in SKOV3 ovarian cancer cells overexpressing HE4 compared to null
vector cells (data not shown). This finding prompted us to begin to characterize septin2’s role in EOC, as it had not been previously documented in the literature. To
establish the clinical relevance of septin-2 in EOC, we evaluated its levels in EOC
samples of a variety of histopathologies and compared these to levels in benign
controls. Immunohistochemical analysis of septin-2 levels in a human ovarian tissue
microarray comprising normal, serous, mucinous, clear cell, and dysgerminoma
histopathologies revealed that mean intensity of the septin-2 staining was statistically
significantly greater in serous EOC (703.3889 pixels) than in adjacent normal tissue
(539 pixels) (p=0.0037) (Fig.1a). While all other histopatholgies exhibited higher
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mean intensity levels of septin-2—mucinous (603 pixels), clear cell (821 pixels), and
dysgerminoma (744 pixels)—compared to the normal adjacent tissue, none where
considered statistically significant possibly due to low numbers of samples available.
To further investigate expression levels of septin-2 in patient samples,
immunohistochemistry of septin-2 was performed in EOC and benign tissue from our
institution. Integrated optical density (IOD) was calculated for each sample, which
revealed statistically significant higher levels in serous (721 area*mean/1E+06,
p=0.04) (Fig 1b. and 1c.) and clear cell (31 area*mean/1E+06, p=0.009)
histopathologies (Fig.1d. and 1e.) compared to respective benign controls (239
area*mean/1E+06) and (6 area*mean/1E+06).

Stable knockdown of septin-2 influences cell proliferation
In order to study septin-2’s function in EOC, stable septin-2 knockout shRNA clones
were generated in human serous ovarian SKOV3 wild type (WT) cells. Two clonal
populations were employed for these studies—knockout 9 (KO9) and knockout 11
(KO11)—based on confirmation of successful septin-2 downregulation. A stable line
was also generated by clonal expansion of cells transfected with control shRNA,
designated Plasmid C. To confirm the efficacy of knockdowns at the genomic level,
qPCR was employed. Septin-2 levels in KO9 were 1.93- and 4.16-fold lower than WT
and Plasmid C cells, respectively. Septin-2 levels in KO11 were 1.67- and 3.88-fold
lower than WT and Plasmid C cells, respectively (Fig 2a).
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To further validate successful knockdown of septin-2, protein levels were detected by
western blot. We observed substantial decreases septin-2 levels in KO9 and KO11
compared to the WT and Plasmid C controls (Fig 2b). Septin-2 levels in KO9 were
decreased by 72% compared to WT and by 62.3% compared to Plasmid C. Septin-2
levels in KO11 were reduced by 76.4% and 67.7% compared to WT and Plasmid C,
respectively (Fig.2c).
To begin to determine the consequence of septin-2 knockdown in SKOV3 cells,
proliferation of the shRNA clones was evaluated. WT, Plasmid C, KO9, and KO11
cells were seeded at equal cell densities and allowed to expand. The cells were
trypsinized at 72 and 96 hours, and numbers of live cells in each clonal population
were quantified (Fig 2d). At 72 hours, KO9 clones exhibited a 67.5% decrease in cell
proliferation compared to WT, and a 60.4% decrease compared to Plasmid C. KO11
clones demonstrated a 66.4% and 59.1% decrease in proliferation from respective WT
and Plasmid C cell numbers. The 96-hour timepoint revealed a 51.1% reduction in
KO9 cells compared to WT and a 39.3% reduction compared to Plasmid C. KO11
cells showed a 62.6% and 53.6% decrease compared to WT and Plasmid C cells,
respectively. All decreases in cell counts displayed by KO9 and KO11 at both
timepoints were determined to be statistically significant (p<0.02). This finding
strongly suggests that the downregulation of septin-2 has a profound impact on cell
proliferation in EOC cells.
Proteomic analysis of septin-2 knockdown in EOC cells
A comparative label-free proteomic analysis was performed to examine global protein
expression level differences resulting from the knockdown of septin-2. Interestingly,
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significant differences in protein-peptide levels between control cells and septin-2
knockouts was observed only in KO11 populations, even though our proliferation
results demonstrated that KO9’s phenotype was similar to that of KO11. We
concluded that it was possible that the knockdown resulted in less significant effects
on protein levels, but still enough to affect proliferation, or that spontaneous loss of
the knockdown had occurred during cell culture. Therefore, we proceeded with
analysis using KO11 cells. As expected, a principal component analysis of three
biological replicates of WT, Plasmid C, and KO11 revealed separate clusters when
comparing principal component 1 and principal component 2 scores (Fig.3). In
contrast, for KO9 sample, the 3 biological replicates were very scattered (Data not
shown). Therefore, for any further analysis or validation process KO9 was not
included.
Mass spectrometry of the control and knockdown cells identified 19976 unique
peptides corresponding to 3565 unique proteins. Of those, only one peptide/protein in
Plasmid C exhibited an absolute fold change greater than 1 with a q-value < 0.05
compared to WT (Fig 4a). This result allowed us to conclude that there was no
significant difference between both control cell populations. Conversely, 5% of all
peptides in KO11 cells revealed relative fold change greater than 1 (q<0.05) compared
to WT cells. In addition, 93.5% of those peptides identified as exhibiting substantial
expression differences displayed a lower peak area in KO11 than WT, indicating a
majority of peptides was downregulated (Fig 4b). Representative examples of peakarea of four peptide sequences from the proteins galetin-3 binding protein
(LFALS3BP), transketolase (TKT), poly(A) binding protein (PABPC4), and enolase-
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1(ENO1) show differential expression between control and knockdown cells.
KO11/WT peak area ratios were calculated for LFALS3BP (0.051, q=0.012), TKT
(0.081, q=0.0012), PABPC4 (0.50, q=0.011), and ENO1 (632.7, q=0.30) (Fig 4c). It is
interesting to note that, all four of these proteins have previously been shown to play a
role in tumorigenesis [24–27]. Heat maps were constructed to illustrate the clustering
of the 231 differentially expressed proteins in each of the three replicates of WT,
Plasmid C, and KO11 (Fig 5a) and representative peptides in the most differentially
expressed proteins (Fig 5b). Comparison of both heat maps reveals an overall similar
pattern of peak-area quantitation, with many of the proteins and peptide sequences
within KO11 exhibiting downregulation compared to WT and Plasmid C controls.
Finally, gene ontology (GO) analysis with differentially expressed proteins showed
enrichment of for, proteasomal/ubiquitin in the biological process category and RNA
binding in the molecular function category (Fig 6). Enrichment was also noted for
terms related to the ribonucleoprotein complex and cytosol in the cellular component
category. KEGG pathway analysis revealed citric acid cycle (TCA cycle) and
spliceosome enrichment among differentially expressed proteins (Fig 6).
Representative proteins related to these pathways were further validated by
immunoblot analysis. Enolase, LDHA, Transketolase, and FASN expression in WT
and KO11 was examined via western blot. (Fig 7a.) Band density normalized to
GAPDH revealed a 7.8% increase in Enolase expression from WT to KO11. A
corresponding 24.2%, 52.6%, and 64.9% decrease was observed comparing WT and
KO11 in LDHA, Transketolase and FASN levels respectively. (Fig 7b.)
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IV.5 Discussion
For the first time, we have characterized septin-2 function in EOC and examined its
proteomic effects on a global level. Several biological pathways were found to be
differentially regulated in septin-2 knockout ovarian cancer cells, exemplified by
representative proteins from (Fig 4c.) Galectin-3 is a member of the β-galactoside
binding protein family that is involved in diverse functions inherent to cancer, such as
metastasis, immune surveillance, inflammation, apoptosis, molecular trafficking, and
mRNA splicing [28]. Transketolase is a pentose phosphate pathway enzyme essential
for cancer growth due to its ability to control NADPH production and counteract
oxidative stress [26]. Poly(A) binding protein is a highly conserved protein that plays
an important role in mRNA stabilization and translation [29], which controls cell
growth, proliferation, and differentiation [30]. Enloase1, found to be differentially
expressed in cancer, is a key glycolytic enzyme that catalyzes 2-phosphogylgerate to
phosphoenolpyruvate in the last steps of the glycolytic catabolic pathway [31].
Of these pathways identified, it was most expected that autophosphorylation and
proteasomal/ubiquitin protein functions were affected by septin-2 knockdown. It has
been previously established that proper control of septins’ phosphorylation status is
required for the completion of cytokinesis [32]. In fungus, Meseroll et. al (2013)
discovered that changes in specific phosphorylation sites on septins (Cdc3p and
Cdc11p) leads to the disruption of higher order septin structures, indicating septin
phosphorylation is also a vital regulator of their own structure formation [33].
Similar to phosphorylation, ubiquitination represents another important septin posttranslational modification. Septins have an established role interacting with proteins
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involved in degradation pathways, such as ubiquitin ligases and de-ubiquitylating
enzymes, which modulates protein turnover [12,34,35]. Recently, it has also been
reported that SUMOylation of human septins is a critical process contributing to
proper septin filament bundling and cytokinesis [36]. Unlike ubiquitin, SUMO (small
ubiquitin-like modifiers) modification does not always lead to protein degradation, as
SUMOylation can also modulate localization, interaction, and activity of the target
protein [37]. Ribet et.al (2017) reported that septin-7 is constitutively SUMOylated
throughout the cell cycle, and septin variants that are unable to be SUMOylated halt
septin bundle formation and lead to defects in cytokinesis, highlighting its crucial role
in septin filament bundling and cell division [36].
GO analysis revealed that septin-2 is also involved in post-transcriptional
modifications, as the spliceosome pathway was found to be enriched among septin-2
regulated proteins (Fig 6). This result suggests that septin-2 plays a major role in the
editing of both precursor messenger RNA (pre-mRNA) and proteins. The
spliceosome, a large molecular complex involved in the removal of non-coding introns
from pre-mRNA, represents a potential oncogenic target as evidence has shown that
tumors rely on normal spliceosome function for cell survival [38,39]. In addition,
Poly(A) binding protein, which we reported as an example of a differentially
expressed protein (Fig. 4c), is a translation initiation factor that binds to the mRNA
3’poly(A) tail [30] and also influences cell growth and survival. Since we have shown
that the knockdown of septin-2 promotes irregular expression of a multitude of
pathways related to mRNA and protein modifications, it seems reasonable that its
downregulation would also affect tumor cell growth.
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As the depletion of septins can lead to cytokinesis failures, it is logical that cellular
proliferation would subsequently be affected. [36] In this study, we observed a
reduction in proliferation with septin-2 knockdown. (Fig.2d) Corroborating results
from our study in EOC, Zhang et. al (2016) treated breast cancer cells with the broad
septin inhibitor forchlorfenuron(FCF) and also observed a decrease in cell
proliferation [15], which they attributed to the suppression of MEK and ERK1/2
(extracellular signal-regulated kinase 1/2) signaling [15]. Another study showed that
septin-8 interacts with MAPK5 (mitogen activated protein kinase 5), further
suggesting that septins play a role in the MAPK/ERK pathway [40]. Septin-9 has also
been implicated in cell proliferation, as a septin-9 variant SEPT9_i1 binds to c-Jun-N
terminal kinase (JNK), preventing its degradation and therefore promoting tumor cell
proliferation [4]. In addition, another septin-9 variant SEPT9_i3 has been found to be
phosphorylated by cell-cycle-dependent kinase 1 (CDK1), controlling entry into
mitosis and promoting cell survival and proliferation [41]. These investigations
highlight that septin-2, and septins in general, play an important role in cellular
proliferation and potentially promote tumor growth.
Interestingly, the most novel conclusion drawn from this investigation was the robust
enrichment seen in cellular metabolism and energy dynamics in proteins affected by
septin-2 downregulation. This novel finding regarding septin-2 is in agreement with
previous studies reporting on septin functions related to energy metabolism. One study
identified that fungal septins FaCdc3 and FaCdc12 are required for lipid metabolism
[42]. In addition, septin-9 was found to induce lipid droplet growth through binding to
phosphatidylinositol-5-phosphate(PtdIns5P), a phospholipid with a well-established
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role in dynamics and intracellular membrane trafficking [43]. PtdIns5P binding in turn
controls septin-9 filament formation and its interaction with microtubules [44].
Furthermore, septin-11 was found to be expressed in human adipocytes and
upregulated in obese individuals. SEPT11 mRNA was positively correlated with
markers of insulin resistance in adipose tissue, and silencing of septin-11 muted
insulin signaling and insulin-induced lipid accumulation in adipocytes [45].
Our findings, however, represent the first time a septin family member has been
implicated in cellular metabolism as it relates to tumorigenesis. Acetyl-CoA, one of
the pathways most differentially expressed by septin-2, is a key metabolic player that
links glycolysis, fatty acid oxidation, ketogenesis, amino acid metabolism, the TCA
cycle, and lipid synthesis [46]. In normoxic conditions, acetyl-CoA is derived from
glucose. However, under hypoxic conditions like in cancer, acetyl-CoA has been to
found to derive from acetate, suggesting that targeting the acetyl-CoA pathway in
cancer could represent a viable treatment option [47]. The TCA cycle, another
important metabolic pathway, was also deregulated in the septin-2 knockdown clones.
While previous dogma stated that tumor cells do not utilize the TCA cycle for energy,
it has now been found that some cancer cells with deregulated oncogenes and tumor
suppressor genes actually do rely on the TCA cycle [48]. In addition, the metabolic
proteins transketolase and enolase, which are involved in glycolysis and the pentose
phosphate pathway, respectively, were found to be differentially expressed by septin-2
inhibition (Fig 4c), demonstrating that septin-2 is involved in various facets of cellular
metabolism within EOC. Pathways related to metabolism and energy production have
previously been found to contribute to EOC tumorigenesis, as it has been shown that
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glycolysis drives chemoresistance in EOC and that high levels of fatty acid synthase
(FASN) contribute to tumor cell growth through the promotion of human epidermal
growth factor [49,50]. Therefore, it can be hypothesized that the inhibition of septin-2
would exhibit a therapeutic effect in EOC via suppression of tumor metabolic
pathways.
Overall, our study demonstrates the novel finding that septin-2 is involved in EOC
pathogenesis. This investigation represents a springboard for future studies to
determine the efficacy of septin-2 inhibition, in addition to more clearly elucidating its
diverse mechanistic pathways in EOC tumorigenesis. While our proteomics study was
performed in a serous ovarian cancer cell line, it would be interesting to repeat the
stable knockdown experiment in a clear cell EOC line, since septin-2 was also found
to be overexpressed in this histopathology. Additionally, both in vitro and in vivo
studies could be performed to confirm that inhibition of septin-2 affects cell viability
and tumor growth in order to determine if targeting of septin-2 synergizes with
platinum-based chemotherapeutics.
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Figure IV. 1 Septin-2 is overexpressed in EOC
(a.) Tissue Microarray analysis reveals that septin-2 is overexpressed
significantly(p=.0037) in serous EOC compared to adjacent normal control.
Mucinous, clear cell, and dysgerminoma all exhibited a non-significant increase in
septin-2 expression (mean intensity) (b.) Staining of human EOC tissue showed a
statistically significant higher(p=0.04) septin-2 expression in serous compared to
benign serous. (c.) Representative images of Serous EOC staining (left panel) vs
benign (right panel). (b.) Staining of human EOC tissue showed a statistically
significant higher(p=0.009) septin-2 expression in clear cell compared to benign
tissue. (e.) Representative images of clear cell EOC staining (left panel) vs benign
(right panel).
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Fig.IV.1(a)
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Fig IV.1(b-e)
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Figure IV.2 Stable septin-2 knockdown shows a decrease in proliferation
(A.) Gene expression levels of septin-2 in KO9 and KO11 where significantly
decreased (p<0.01) compared to WT and plasmid c control levels. (B.) Septin-2 is
decreased in KO9 and KO11 at the protein level. (C.) Relative band density of (B.).
(D.) Proliferation rates of KO9 and KO11 were significantly lower (p<0.02) at both 72
and 96 hours compared to control WT and plasmid c.
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Fig.IV.2
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Figure IV.3 Principal Component Analysis of CO
WT, Plasmid C, and KO11 samples show clustering based on grouping. However, WT
is more dispersed and shows overlap with Plasmid C. Visualization of principal
component 1(PC1) versus principal component 2 (PC2).
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Fig IV.3
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Figure IV.4 Volcano plot of fold change versus q-value of peak area for distinct
peptides
Of the 19976 distinct peptides (3565 proteins) identified, (A) only one peptide/protein
(0%, red in inset pie chart) in Plasmid C and (B) 5.0% peptides in KO11 showed large
difference (absolute fold change more than 1, and q < 0.05) against WT. Nearly 93.5%
peptides showed lower peak-area (down regulation) in KO11. (C) represents the
examples of peak-area/expression levels in replicates for four peptides are shown: 1.
Galectin-3-binding protein (LGALS3BP, K7EKQ5), 2. Transketolase (TKT, P29401),
3. Poly(A) binding protein 4 (PABPC4, Q4VC03), 4. Enolase 1 (ENO1, P06733). The
peptide sequence, KO11/WT peak-area ratio and respective q-values are listed for
each protein.
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Fig.IV.4
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Figure IV.5 Hierarchical clustering and heat map of differentially expressed proteins
and peptides
(A.) Clustering of the 231 differentially expressed proteins (B.) Peptides in most
differentially expressed proteins, for example, Q9P2E9 (RRBP1, Ribosome binding
protein 1) with 60 peptides, showing an overall similar pattern of peak-area
quantitation.
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Fig.IV.5
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Figure IV.6 Gene ontology (GO) analysis
Gene ontology (GO) analysis using DAVID (https://david.ncifcrf.gov/). Proteins with
differential expression (n = 231, q < 0.05, in KO11 versus WT is compared with
proteins (n = 3334) that showed no differential expression. Former showed enrichment
for proteasomal/ubiquitin related GO terms (q << 0.05, Bonferroni) in biological
process (BP) category. In cellular component (CC) and molecular function (MF)
categories, differentially expressed proteins showed enrichment for ribonucleoprotein
and RNA related terms. No enrichment was seen in molecular function category.
Differentially expressed proteins showed enrichment for KEGG pathways relating to
citrate cycle/energy and spliceosome.
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Fig.IV.6
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Figure IV.7 Verification of Enriched Proteins Identified by Proteome Analysis
(A.) Western Blot analysis of protein expression validated in both WT and KO11 (B.)
Relative Band Densities of proteins in (A.), normalized to GAPDH.
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Fig.IV.7
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CHAPTER 7
CONCLUSION

Epithelial ovarian cancer (EOC) is such a deadly disease largely owing to the two
major challenges of diagnosis and treatment. Ovarian cancer is detected at a late stage
when tumor cells have already detached and metastasized directly into the peritoneal
cavity, making it challenging for all lesions to be removed surgically [1]. Therefore,
extensive disease remains in the body even after surgery. While treatment has evolved
to include PARP inhibitors and anti-angiogenic therapies, prognosis remains poor.
Immunotherapies for the treatment of cancer have recently garnered much attention, as
it has been observed that the number of intratumoral T-cell numbers correlate to a
better clinical outcome [2]. However, establishing a breakthrough immune target for
ovarian cancer has been met with challenges, as the response rate remains low [3].
Therefore, a critical need for novel therapies for EOC still exists.
HE4 plays a unique role in EOC as it has been implicated in both diagnosis and
prognosis of the disease. As a clinical biomarker, HE4 represents a promising early
detection method. Compared to the more established biomarker CA-125, it is less
frequently elevated in benign disease and is potentially able to identify patients that
are at high risk for primary platinum resistance [4]. While much is known about HE4
clinically, far less is known about its biological functions in EOC. The goal of this
investigation was to determine the mechanisms in which HE4 drives ovarian
pathogenesis, and to ultimately provide evidence as to whether HE4 should be
recommended as a therapeutic target for EOC.
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As HE4 was initially suggested to have a potential role in innate immunity, [5] these
studies aimed to better understand HE4’s function in tumor immunity. For the first
time, this investigation has shown that HE4 is involved in promoting ovarian tumor
immune evasion, through influencing expression of two proteins, osteopontin (OPN)
and dual specificity phosphatase 6 (DUSP6). Subtractive hybridization revealed that
when peripheral blood mononuclear cells (PBMCs) were treated with recombinant
HE4, OPN was the most downregulated protein, and DUSP6 was the most
upregulated.
OPN is a secreted glycoprotein that has been identified as having important T helper 1
(Th1) cytokine functions. [6]Specifically, it was discovered that HE4 suppresses OPN
in CD3+ T cells, while also impairing the secretion of IL-12 and IFN-γ, two important
cytokines downstream of OPN that promote T-cell survival [6,7]. Furthermore, when
ovarian cancer cells were cultured with media from PBMCs cultured with recombinant
HE4, those cells were less susceptible to cell death, which was reversed upon silencing
of HE4. Also, in human EOC patient tissue, serum HE4 levels inversely correlated to
the number of OPN positive T cells in patient tumors.
The second objective in defining HE4’s role in tumor immunity was to delineate the
effect of HE4’s upregulation of DUSP6. DUSP6 is an extracellular signal-regulated
kinase (ERK) phosphatase that has been found to regulate CD4+ T cell activation and
differentiation through the inhibition of T-cell receptor (TCR) dependent ERK
activation [8]. Interestingly, upon testing HE4’s upregulation of DUSP6 in specific
subsets of cells within PBMCs, the upregulation was found to be restricted to CD8+
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T-cells and CD56+ natural killer (NK) cells, and not CD4+ T cells. It was also
discovered that HE4 promotes ERK ½ phosphorylation in these cell populations. Upon
co-culture of PMBCs with ovarian tumor cells it was found that adding recombinant
HE4 enhanced cell proliferation. However, this effect was attenuated by the addition
of an allosteric DUSP6 inhibitor (BCI). PBMCs devoid of CD8+/CD56+ cells did not
produce the same result, proving that CD8+ and CD56+ populations were solely
responsible for the observed effects. This result was particularly interesting in light of
HE4’s hypothesize role in innate immunity, since NK cells, as part of the innate
immune response, have been found to play an important role in helping tumor cells
escape immune surveillance [9].
These two studies indicate that through targeting of HE4, it may be possible to restore
a normal tumor immune response. To confirm this, future directions include testing
the inhibition of HE4 via a neutralizing antibody in an immune competent mouse
model to see how this affects tumor burden. In addition, testing HE4 inhibition in vivo
in combination with platinum-based chemotherapeutics and immune checkpoint
inhibitors to determine synergistic effects is important. Results from these studies will
be valuable, as many successful EOC regimens are combination therapies that produce
higher response rates and lower resistance rates compared with monotherapies [10].
Before HE4 can truly be recommended as a novel therapy that can remedy tumor
immune evasion, results from these in vivo experiments should be obtained.
The study of DUSP6 and HE4 in immune cells lead to an additional investigation that
examined DUSP6’s role in epithelial ovarian cells. This was of particular interest since
DUSP6 has not been well defined in cancer, and it has been published that HE4
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interacts with the ERK signaling pathway in EOC [11–13]. This study confirmed that
DUSP6 functions similarly to HE4 in EOC pathogenesis, as the inhibition of both
factors promotes apoptosis in EOC cells. Furthermore, DUSP6 is overexpressed in
serous EOC patient tissue and intratumoral levels of HE4 and DUSP6 correlate. Since
it has been published that HE4 promotes chemoresistance in EOC [14], the effect of
DUSP6 on platinum response was also evaluated. When DUSP6 was inhibited with
BCI in combination with carboplatin and paclitaxel, it produced a synergistic response
over single-agent chemotherapeutic. To assess downstream effects of this inhibition, it
was shown that BCI altered genomic levels of the ERK related response genes early
growth response protein 1 (EGR1), a strong promoter of apoptosis and proto-oncogene
c-Jun [15]. EGR1 was upregulated in cells co-treated with BCI and either paclitaxel or
carboplatin, compared to a single-agent treatment, while c-Jun expression was
decreased upon co-treatment. This study was able to define a new role for DUSP6
within EOC, indicating that targeting this factor is important both to restore proper
tumor immune function and to overcome chemoresistance in EOC cells.
Moreover, as HE4 has the ability to be detected in patient serum, it would be
interesting to determine if DUSP6 could also be detected in patient blood. Additional
future directions include establishing stable DUSP6 knockdown and overexpressing
clones to test cancer related phenotypes. Furthermore, as HE4 overexpressing and
stable knockout cell lines have been previously established, global genomic arrays
could then be performed to establish similarities and differences between the
overexpression and knockout populations of each factor.
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Finally, the last part of this thesis sought to characterize the novel protein septin-2 in
EOC. Septin-2 is a member of the septins protein family, which comprises 13 GTP
binding proteins that play important roles in various cellular processes including
cytokinesis [16,17]. Septin-2 was identified in a small proteomics study as most
enriched with HE4 immunoprecipitation in HE4 overexpressing cells versus null
vector cells. For the first time, this study revealed that septin-2 is overexpressed in
both serous and clear cell EOC patient tissue. Establishment of stable knockout clones
in an ovarian cell lines showed that proliferation was drastically decreased in septin-2
knockout clones. Global proteome analysis was employed to determine the relevant
pathways in which septin-2 is involved with in EOC, revealing that down regulation of
septin-2 produced differential expression of major metabolic and cellular energy
pathways.
As this was a pilot study with the simple goal of defining septin-2 in EOC, more
research needs to be completed in order to understand its mechanistic role in ovarian
tumorigenesis. Future directions involve an in vivo study to determine if septin-2
knockout lead to a decrease in tumor growth, alike to the reduction of cell proliferation
observed in vitro. Furthermore, it will also be important to elucidate the mechanistic
relationship between septin-2 and HE4, in addition to determining how septin-2 and
HE4 interact with metabolic and cellular energy pathways. This is an especially
original finding as both proteins have not been previously found to interact with
cellular metabolism and may lead to new novel therapeutic targets for EOC.
As a reputable clinical biomarker, HE4 is valuable in the diagnosis and prognosis of
EOC; however, knowledge of its role in treatment of EOC is deficient in comparison.
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Overall, this thesis compilation improves the understanding of HE4’s diverse
biological function in EOC, through highlighting its role in the promotion of tumor
immune dysfunction and characterizing novel interacting proteins. As there is a dire
need for innovative targeted therapies for EOC patients, this thesis presents new
evidence that inhibiting HE4 represents promise not only in downregulating molecular
mechanisms that promote tumorigenesis, but also in restoration of normal tumor
immune function. Furthermore, global genomic and proteomics analysis of differential
HE4 levels revealed its relationship to novel factors that had not previously been
characterized in EOC prior to this investigation. Taken as a whole, this dissertation
offers original insights that emphasize the importance of HE4’s role in the
pathogenesis of EOC.
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